var title_f18_8_18560="Arthritis mutilans PI";
var content_f18_8_18560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arthritis mutilans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows a patient with arthritis mutilans caused by psoriatic arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18560=[""].join("\n");
var outline_f18_8_18560=null;
var title_f18_8_18561="Torsion with nonviable ovary";
var content_f18_8_18561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlarged left ovary found torsed upon laparotomy demonstrating a dark, dusky appearance secondary to venous lymphatic congestion in the setting of continued arterial perfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18561=[""].join("\n");
var outline_f18_8_18561=null;
var title_f18_8_18562="Medium CMN";
var content_f18_8_18562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medium-sized congenital melanocytic nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the pebbly surface and mild hypertrichosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18562=[""].join("\n");
var outline_f18_8_18562=null;
var title_f18_8_18563="Gross path bronchogenic cyst";
var content_f18_8_18563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathology specimen of a bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cyst is intraparenchymal and unilocular. The incision shows the smooth interior.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher Oermann, MD and Claire Langston, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18563=[""].join("\n");
var outline_f18_8_18563=null;
var title_f18_8_18564="Gentamicin (systemic): Patient drug information";
var content_f18_8_18564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gentamicin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/47/761?source=see_link\">",
"     see \"Gentamicin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/63/8185?source=see_link\">",
"     see \"Gentamicin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8107109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gentamicin Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney function to get worse and hearing loss, and it may change your sense of balance. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gentamicin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hearing loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some side effects may happen up to 2 weeks after the shot. Report them to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11694 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18564=[""].join("\n");
var outline_f18_8_18564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107109\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031192\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031194\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031193\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031198\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031199\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031201\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031196\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031197\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031202\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031203\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/21/3412?source=related_link\">",
"      Gentamicin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/23/28020?source=related_link\">",
"      Gentamicin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/36/37443?source=related_link\">",
"      Gentamicin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/47/761?source=related_link\">",
"      Gentamicin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/63/8185?source=related_link\">",
"      Gentamicin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/46/17123?source=related_link\">",
"      Gentamicin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/59/38835?source=related_link\">",
"      Gentamicin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/20/31042?source=related_link\">",
"      Gentamicin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_8_18565="Junctional EB Herlitz 4";
var content_f18_8_18565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive areas of denudation in junctional EB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18565=[""].join("\n");
var outline_f18_8_18565=null;
var title_f18_8_18566="Management of the potential deceased donor";
var content_f18_8_18566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the potential deceased donor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Ron Shapiro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Michael A Devita, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18566/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/8/18566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 50 percent of kidneys and most of the extrarenal solid organs that are transplanted are recovered from deceased donors. Most deceased donor organs are recovered from donors who meet criteria for brain death and have ongoing cardiac function. Brain death is irreversible, and the ability to recover transplantable organs exists only because the technology of the intensive care unit can maintain physiologic homeostasis, including circulation and respiration. Without this support, \"brain death\" occurs almost simultaneously with \"cardiac death.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The issues involved in the pre-recovery medical management of the deceased donor will be discussed here. Issues related to the determination of brain death and the selection and preservation of donated organs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/9/21656?source=see_link\">",
"     \"Donor selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSICIAN RESPONSIBILITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recovery of viable organs for transplantation is dependent upon appropriate medical management both before and after death is determined, regardless of whether brain criteria or cardiac criteria for death are utilized. Even with intensive care support, the brain dead donor can be challenging to manage because the pathophysiologic changes induced by brain death upset homeostasis. The medical team managing the potential donor must anticipate and prevent (preferably) or detect and treat abnormalities that can cause circulatory collapse or permanent damage to otherwise transplantable organs.",
"   </p>",
"   <p>",
"    Clinicians who care for critically ill or injured patients in the emergency department, intensive care unit (ICU), or operating room must be able to recognize potential organ donors and be aware of the criteria for brain death and organ donation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States, the Centers for Medicare and Medicaid Services require that the option of organ donation be discussed only by individuals with specialized training in this area [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Most authors agree that requests by the organ procurement coordinator along with the treating physician represent the most effective approach to organ donation. In addition, efficient coordination among these physicians, organ procurement organizations, and transplant centers to promote the best physiologic donor management is required to maximize the number of viable organs available for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This is particularly important in specialized high-volume trauma centers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the system of deceased donor organ donation is based upon &ldquo;explicit consent,&rdquo; in which the individual is assumed to not be a donor unless the individual indicates their wish of becoming an organ donor upon their death. The decision to donate must be registered by the individual or is expressed by family members at the time of death. By comparison, there is a system of &ldquo;presumed consent&rdquo; in many other nations, in which the individual who is against donating an organ must either register their desire or express this desire to a family member. If this has not occurred, it is assumed that the person is an organ donor. Deceased donor kidney transplantation rates are higher in nations with &ldquo;presumed consent&rdquo; compared with those with an &ldquo;explicit consent&rdquo; system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/7\">",
"     7",
"    </a>",
"    ]. However, living donor kidney transplantation rates are lower in nations with presumed consent. The underlying reasons for this difference are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death sets in motion a number of pathophysiologic responses, not all of which are understood, that are harmful to the function of potentially transplantable organs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/8\">",
"     8",
"    </a>",
"    ]. Donor management involves a complex resuscitative effort to overcome these problems and maximize the potential viability of all organs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The basic management goals are to achieve hemodynamic stability and optimal function of all organs that may be transplanted.",
"   </p>",
"   <p>",
"    This process requires balancing the interventions needed for the successful preservation of multiple organs. Interventions that improve the function of one organ may be detrimental to the function of other organs. As an example, although the renal transplant team prefers an extremely well-hydrated donor with excellent diuresis, overhydration may jeopardize the transplantability of the heart, lungs, liver, and pancreas.",
"   </p>",
"   <p>",
"    Other important general considerations are the maintenance of proper ventilatory support, good pulmonary toilet, and appropriate infection prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/8\">",
"     8",
"    </a>",
"    ]. Normothermia should be maintained passively on all brain dead cadavers using blankets. A temperature less than 35 degrees centigrade requires use of active rewarming modalities, such as a warm air blanket.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic hypotension is common in brain-dead deceased donors (up to 80 percent), and may be caused by lack of sympathetic tone, central diabetes insipidus, adrenal insufficiency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deliberate volume restriction prior to the determination of brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/8\">",
"     8",
"    </a>",
"    ]. Hypovolemia related to blood loss may also contribute, particularly in trauma victims. Adequate volume resuscitation is therefore critically important to ensure donor viability, and is the first step in correcting low blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, since volume resuscitation may not be sufficient to improve blood pressure because of a loss of vascular tone, inotropic or pressor support may be a necessary adjunct. Many clinicians start with dopamine, but other agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , norepinephrine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    , may be required. Using the lowest dose of the least injurious agent is the preferred approach, but this is not always possible. The goal is to achieve a normotensive, euvolemic state [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/8\">",
"     8",
"    </a>",
"    ]. For patients who require vasopressor support, a central venous catheter may be useful to help guide therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENDOCRINE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important endocrine problem in the brain dead donor is central diabetes insipidus, caused by inadequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     antidiuretic hormone",
"    </a>",
"    (ADH) production within the posterior pituitary gland. Hypotonic urine volumes exceeding 1000",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    may be seen and can be devastating if not treated adequately [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/11\">",
"     11",
"    </a>",
"    ]. Although volume replacement will help ensure euvolemia, excessive diuresis is more easily managed by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    to keep urine output in the 100 to 200 mL per hour range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adrenal insufficiency is also common following brain death. As an example, a retrospective study noted low baseline cortisol levels and impaired response to ACTH stimulation in 76 percent of patients who met criteria for brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, thyroid abnormalities, including the \"sick euthyroid syndrome\" are also prevalent after brain death. Some authors have demonstrated that more transplantable organs may be able to be recovered from deceased donors who have received thyroid supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to counteract all of the effects described above, administration of triple therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and a single dose of either triiodothyronine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    has been advocated to help promote hemodynamic stability in deceased donors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/8,15-18\">",
"     8,15-18",
"    </a>",
"    ]. While the efficacy of this approach has not been validated, it is used commonly in organ procurement organizations around the country.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal donor management remains important when the donor is taken to the operating room for organ recovery. The same principles described above apply to the intraoperative setting. In the case of a multiple organ donor, for example, the operative time prior to aortic cross-clamping may be relatively long, as both the thoracic and the abdominal organ recovery teams will require time for preliminary dissection of their respective organs. Assuring hemodynamic stability and good diuresis during this period is a key part of successful organ recovery. Immediately prior to aortic cross-clamping,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (at a dose of 300",
"    <span class=\"nowrap\">",
"     units/kg)",
"    </span>",
"    is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DONATION AFTER DEATH DETERMINED USING CARDIAC CRITERIA (NON-HEART-BEATING DONOR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, a situation will occur where a potentially suitable donor is identified who does not meet criteria for brain death but has no hope of any sort of viable recovery, and in whom life sustaining treatment is withdrawn. After death is determined using standard cardiopulmonary criteria (permanent absence of respiration, circulation, and responsiveness), organs may be procured for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In this setting, recovery of the kidneys, the liver, and the pancreas can be attempted, but only after the ventilator has been disconnected, the heart has stopped beating, and the patient has been determined to be dead using cardiopulmonary criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. This is referred to as donation after cardiac death (DCD).",
"   </p>",
"   <p>",
"    This procedure is best performed in the operating room setting, to minimize the warm ischemic time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Potential donor patients are generally receiving life-sustaining therapy, and would ordinarily be expected to expire within a very short amount of time after discontinuation of life support. Practically speaking, this includes patients on ventilators, intraaortic balloon pumps, ventricular assist devices,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high dose vasopressor or inotrope therapy.",
"   </p>",
"   <p>",
"    Prior to the loss of circulation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    must be administered to decrease the risk of thrombosis. Usually, only 30 to 45 minutes of warm ischemia can be tolerated. This time can be calculated from the time of onset of hypotension or hypoxemia until the time the organs have been cooled although some centers advocate calculating the time from when the support is withdrawn until the time the organs are cooled [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite an increased incidence of poor initial allograft function, some centers have reported long-term survival rates of kidneys from donors after cardiac death comparable to those observed with kidneys recovered from heart-beating and living donors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/21,26-29\">",
"     21,26-29",
"    </a>",
"    ]. In a single center study, for example, the one and five year renal allograft survival rate was 87 and 82 percent for transplants from non-heart beating donors, 91 and 86 for transplants from heart beating donors less than 60 years of age, and 80 and 73 percent for transplants from heart beating donors greater than 60 years of age, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited experience suggests that this approach can also be used for liver and lung transplantation, provided that the warm ischemic time is minimized [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/23,24,30\">",
"     23,24,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A consensus conference was convened by the HRSA Division of Transplantation and the United Network for Organ Sharing (UNOS) to elucidate areas of difficulty for DCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/31\">",
"     31",
"    </a>",
"    ]. The conference was funded by a number of organizations and had a very broad representation. Group 1 commented and made recommendations for death determination, which requires absent circulation, respiration, and unresponsiveness.",
"   </p>",
"   <p>",
"    The conference participants supported the Society for Critical Care Medicine recommendation that \"at least two minutes of observation is required, and more than five minutes is not recommended\" [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/32\">",
"     32",
"    </a>",
"    ]. Given the emerging consensus of these guidelines, no additional waiting period is warranted after death is certified. A second finding is the recommendation that organizations participating in DCD utilize either the UNOS criteria for determining potential DCD candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/25\">",
"     25",
"    </a>",
"    ], or the University of Wisconsin assessment algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The University of Wisconsin has validated criteria to identify patients who are likely to be able to become DCD after death. These criteria are easily performed and can help decision making regarding whether to proceed with organizing an attempt to perform DCD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18566/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11312482\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 50 percent of kidneys and most of the extrarenal solid organs that are transplanted are recovered from deceased donors. Most deceased donor organs are recovered from donors who meet criteria for brain death and have ongoing cardiac function. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recovery of viable organs for transplantation is dependent upon appropriate medical management both before and after death is determined, regardless of whether brain criteria or cardiac criteria for death are utilized. Even with intensive care support, the brain dead donor can be challenging to manage because the pathophysiologic changes induced by brain death upset homeostasis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physician responsibilities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain death sets in motion a number of incompletely understood pathophysiologic responses that are harmful to the function of potentially transplantable organs. Donor management involves a complex resuscitative effort to overcome these problems and maximize the potential viability of all organs. This process requires balancing the interventions needed for the successful preservation of multiple organs. The goal is euvolemia, normal blood pressure and adequate oxygenation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic hypotension is common in brain-dead deceased donors (up to 80 percent), and may be caused by lack of sympathetic tone, central diabetes insipidus, adrenal insufficiency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deliberate volume restriction prior to the determination of brain death. Adequate volume resuscitation is critically important to ensure donor organ viability. However, volume resuscitation may not be sufficient to improve blood pressure, and pressor support may be necessary as an adjunct. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemodynamic support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Administration of triple therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"       vasopressin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , and a single dose of either triiodothyronine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      has been advocated to help promote hemodynamic stability in deceased donors. While the efficacy of this approach has not been validated, it is used commonly in organ procurement organizations around the country. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Endocrine disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occasionally, a situation will occur where a potentially suitable donor is identified who does not meet criteria for brain death but has no hope of any sort of viable recovery, and in whom life sustaining treatment is also withdrawn. After death is determined using standard criteria, organs may be procured for transplantation (donation after cardiac death). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Donation after death determined using cardiac criteria (non-heart-beating donor)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/1\">",
"      Williams MA, Lipsett PA, Rushton CH, et al. The physician's role in discussing organ donation with families. Crit Care Med 2003; 31:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/2\">",
"      Karciolu O, Ayrik C, Erbil B. The brain-dead patient or a flower in the vase? The emergency department approach to the preservation of the organ donor. Eur J Emerg Med 2003; 10:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/3\">",
"      Guadagnoli E, Christiansen CL, Beasley CL. Potential organ-donor supply and efficiency of organ procurement organizations. Health Care Financ Rev 2003; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/4\">",
"      D&ouml;emeci L, Yilmaz M, Cengiz M, et al. Brain death and donor management in the intensive care unit: experiences over the last 3 years. Transplant Proc 2004; 36:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/5\">",
"      Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines for donor care. Prog Transplant 2004; 14:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/6\">",
"      Shafer TJ, Davis KD, Holtzman SM, et al. Location of in-house organ procurement organization staff in level I trauma centers increases conversion of potential donors to actual donors. Transplantation 2003; 75:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/7\">",
"      Horvat LD, Cuerden MS, Kim SJ, et al. Informing the debate: rates of kidney transplantation in nations with presumed consent. Ann Intern Med 2010; 153:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/8\">",
"      Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.",
"     </a>",
"    </li>",
"    <li>",
"     Boyd, GL, Phillips, MG, Henry, ML. Cadaver Donor Management. In: UNOS, Organ Procurement, Preservation and Distribution in Transplantation, 2nd ed, Phillips, MG (Ed), Richmond, Virginia, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/10\">",
"      Kainz A, Wilflingseder J, Mitterbauer C, et al. Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: a randomized, controlled trial. Ann Intern Med 2010; 153:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/11\">",
"      Smith M. Physiologic changes during brain stem death--lessons for management of the organ donor. J Heart Lung Transplant 2004; 23:S217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/12\">",
"      Szab&oacute; G. Physiologic changes after brain death. J Heart Lung Transplant 2004; 23:S223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/13\">",
"      Dimopoulou I, Tsagarakis S, Anthi A, et al. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med 2003; 31:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/14\">",
"      Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg 2001; 136:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/15\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/16\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003; 75:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/17\">",
"      Lloyd-Jones H, Wheeldon DR, Smith JA, et al. An approach to the retrieval of thoracic organs for transplantation. AORN J 1996; 63:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/18\">",
"      Wheeldon DR, Potter CD, Oduro A, et al. Transforming the \"unacceptable\" donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995; 14:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/19\">",
"      Zawistowski CA, DeVita MA. Non-heartbeating organ donation: a review. J Intensive Care Med 2003; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/20\">",
"      Reich DJ, Mulligan DC, Abt PL, et al. ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation. Am J Transplant 2009; 9:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/21\">",
"      Brook NR, Waller JR, Nicholson ML. Nonheart-beating kidney donation: current practice and future developments. Kidney Int 2003; 63:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/22\">",
"      Kootstra G, Kievit J, Nederstigt A. Organ donors: heartbeating and non-heartbeating. World J Surg 2002; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/23\">",
"      D'alessandro AM, Hoffmann RM, Knechtle SJ, et al. Liver transplantation from controlled non-heart-beating donors. Surgery 2000; 128:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/24\">",
"      Casavilla A, Ramirez C, Shapiro R, et al. Experience with liver and kidney allografts from non-heart-beating donors. Transplantation 1995; 59:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/25\">",
"      Bernat JL, D'Alessandro AM, Port FK, et al. Report of a National Conference on Donation after cardiac death. Am J Transplant 2006; 6:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/26\">",
"      Nicholson ML, Metcalfe MS, White SA, et al. A comparison of the results of renal transplantation from non-heart-beating, conventional cadaveric, and living donors. Kidney Int 2000; 58:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/27\">",
"      Metcalfe MS, Butterworth PC, White SA, et al. A case-control comparison of the results of renal transplantation from heart-beating and non-heart-beating donors. Transplantation 2001; 71:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/28\">",
"      Gok MA, Buckley PE, Shenton BK, et al. Long-term renal function in kidneys from non-heart-beating donors: A single-center experience. Transplantation 2002; 74:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/29\">",
"      S&aacute;nchez-Fructuoso AI, Marques M, Prats D, et al. Victims of cardiac arrest occurring outside the hospital: a source of transplantable kidneys. Ann Intern Med 2006; 145:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/30\">",
"      Steen S, Sj&ouml;berg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/31\">",
"      Bernat JL, Capron AM, Bleck TP, et al. The circulatory-respiratory determination of death in organ donation. Crit Care Med 2010; 38:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/32\">",
"      Ethics Committee, American College of Critical Care Medicine; Society of Critical Care Medicine. Recommendations for Non heart beating organ donation. A position paper by the Ethics committee, American College of Critical Care Medicine; Society of Critical Care Medicine. Crit Care Med 2001; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/33\">",
"      D'Alessandro AM, Fernandez LA, Chin LT, et al. Donation after cardiac death: the University of Wisconsin experience. Ann Transplant 2004; 9:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/34\">",
"      Lewis J, Peltier J, Nelson H, et al. Development of the University of Wisconsin donation After Cardiac Death Evaluation Tool. Prog Transplant 2003; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18566/abstract/35\">",
"      DeVita MA, Brooks MM, Zawistowski C, et al. Donors after cardiac death: validation of identification criteria (DVIC) study for predictors of rapid death. Am J Transplant 2008; 8:432.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7318 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-F2EAE850DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18566=[""].join("\n");
var outline_f18_8_18566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11312482\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSICIAN RESPONSIBILITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEMODYNAMIC SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENDOCRINE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INTRAOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DONATION AFTER DEATH DETERMINED USING CARDIAC CRITERIA (NON-HEART-BEATING DONOR)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11312482\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/9/21656?source=related_link\">",
"      Donor selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=related_link\">",
"      Lung transplantation: Donor lung preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_8_18567="CT axial dilated sm bowel";
var content_f18_8_18567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81165%7EGAST%2F61824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81165%7EGAST%2F61824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel obstruction seen on CT scan showing dilated, fluid-filled loops of small bowel.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Hodin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel obstruction CT (coronal images)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel obstruction seen by CT scan (coronal images) showing dilated, fluid-filled loops of small intestine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Hodin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18567=[""].join("\n");
var outline_f18_8_18567=null;
var title_f18_8_18568="Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy";
var content_f18_8_18568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18568/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18568/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18568/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/8/18568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver's complex vascular supply and high metabolic activity make it particularly vulnerable to circulatory disturbances. The severity and characteristics of hepatic injury depend upon the blood vessels that are involved and the degree to which injury is related to passive congestion or diminished perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several well-recognized forms of vascular injury to the liver, including Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome (veno-occlusive disease), passive congestion due to heart failure, hepatic infarction, and ischemic hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43013?source=see_link\">",
"     \"Pathogenesis of liver injury in circulatory failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will focus on ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy, while discussions on Budd-Chiari syndrome, hepatic sinusoidal obstruction syndrome, and congestive hepatopathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=see_link\">",
"     \"Congestive hepatopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISCHEMIC HEPATITIS (SHOCK LIVER, HYPOXIC HEPATITIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic hepatitis (also referred to as shock liver, hypoxic hepatitis, and occasionally [and erroneously] acute hepatic infarction) refers to diffuse hepatic injury resulting from acute hypoperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/2\">",
"     2",
"    </a>",
"    ]. In one report, ischemic hepatitis accounted for 1 percent of patients admitted to an intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term hepatitis is somewhat of a misnomer since the injury is not mediated by an inflammatory process. Nevertheless, the profound elevation in aminotransferases is similar to that seen in acute viral and toxic hepatitis (such as caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), two disorders that should be considered prominently as part of the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .) The term ischemic hepatitis is preferable to \"shock liver\" since the syndrome can occur in the absence of shock. The diffuse nature of the injury distinguishes it from hepatic infarction, which represents focal injury.",
"   </p>",
"   <p>",
"    The clinical, laboratory, and histologic features of ischemic hepatitis overlap considerably with those of congestive hepatopathy, since the underlying cause of both conditions is related to decreased cardiac output. Many cases of ischemic hepatitis occur in the setting of congestive heart failure, although there are many other potential causes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=see_link\">",
"     \"Congestive hepatopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any cause of shock or hemodynamic instability can cause ischemic injury to the liver, although in some reports only approximately one-half of patients with ischemic hepatitis had shock [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43013?source=see_link\">",
"     \"Pathogenesis of liver injury in circulatory failure\"",
"    </a>",
"    .) Ischemic injury can also be caused by focal interruption of the hepatic blood supply, as occurs with hepatic sickle cell crisis and hepatic artery thrombosis in patients who have undergone liver transplantation or have preexisting portal vein thrombosis (loss of the hepatic artery alone generally does not cause ischemic hepatitis in otherwise healthy people). Ischemic hepatitis has also been described in the setting of severe respiratory failure, systemic hypoxemia, obstructive sleep apnea, and acute lower limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=see_link\">",
"     \"Hepatic manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hemodynamic insult is usually apparent clinically before evidence of liver injury appears. Less commonly, ischemic injury may follow \"subclinical\" circulatory disturbances (due to transient reductions in hepatic perfusion), particularly in patients who are predisposed to ischemic injury such as those with preexisting passive congestion and those with portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic hepatitis is usually first detected because of elevations in liver biochemical tests following a hypotensive episode. Occasional patients have symptoms suggesting acute hepatitis, including nausea, vomiting, anorexia, malaise, and right upper quadrant pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Thus, ischemia should always be considered in the differential diagnosis of acute hepatitis, along with more common causes such as viral infection, drugs, toxins, autoimmunity, and metabolic disorders.",
"   </p>",
"   <p>",
"    The typical pattern of liver biochemical tests consists of a rapid rise in serum aminotransferase levels associated with an early massive rise in lactate dehydrogenase (LDH) levels. Peak aminotransferase levels are typically 25 to 250 times the upper limit of normal and are reached within one to three days of the hemodynamic insult [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of ongoing hemodynamic instability, aminotransferase levels subsequently decline steadily, usually returning to normal within 7 to 10 days. The serum bilirubin level rarely rises above four times the upper limit of normal, usually beginning its rise after aminotransferase levels have begun to decline. Serum alkaline phosphatase levels are rarely higher than twice the upper limit of normal.",
"   </p>",
"   <p>",
"    Hepatic synthetic function usually remains normal or is only mildly impaired; the prothrombin time is infrequently prolonged by more than three seconds. Occasional patients develop changes in mental status, which generally reflect impaired cerebral perfusion rather than hepatic encephalopathy.",
"   </p>",
"   <p>",
"    Hepatopulmonary syndrome develops in nearly one-half of patients but appears to be reversible following normalization of hepatic function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/12\">",
"     12",
"    </a>",
"    ]. The pathogenesis is believed to involve intrapulmonary vasodilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=see_link\">",
"     \"Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic hepatitis should be considered in the clinical settings described above. Few causes of liver injury result in the striking increases in aminotransferase levels (exceeding 1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or 50 times the upper limit of normal) seen in ischemic hepatitis. Besides ischemic hepatitis, the most common are acute viral hepatitis and acute drug- or toxin-induced liver injury (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity, certain herbal medications). On occasion, similar values can be seen in a number of other settings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      During an acute exacerbation of autoimmune hepatitis.",
"     </li>",
"     <li>",
"      Spontaneous reactivation of chronic type B hepatitis.",
"     </li>",
"     <li>",
"      Superimposition of hepatitis D in a chronic carrier of hepatitis B virus.",
"     </li>",
"     <li>",
"      Miscellaneous disorders such as acute Budd-Chiari syndrome (especially those with concomitant portal vein thrombosis), hepatic sinusoidal obstruction syndrome, HELLP syndrome, acute fatty liver of pregnancy, and hepatic infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders cannot be distinguished based upon the pattern of liver biochemical tests alone. However, some features may suggest an ischemic rather than a viral cause of liver injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early rapid rise in the serum LDH level is unusual in viral hepatitis.",
"     </li>",
"     <li>",
"      A ratio of serum alanine aminotransferase to LDH of less than 1.5 early in the course of acute hepatitis suggests ischemic hepatitis rather than viral hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A rapid fall in serum aminotransferase levels after the initial rise is characteristic of ischemic liver injury and atypical for other causes of hepatitis.",
"     </li>",
"     <li>",
"      Ischemic hepatitis is often accompanied by additional evidence of end-organ hypoperfusion, especially acute tubular necrosis of the kidney. Thus, a concomitant, early rise in the serum creatinine level favors a diagnosis of ischemic hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/4,11\">",
"       4,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to a careful medical history, reasonable evaluation might include serologic testing for acute viral hepatitis, a blood",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    level, and a right upper quadrant ultrasound with Doppler studies of the portal and hepatic veins and hepatic artery in addition to evaluation for suspected underlying causes of ischemic injury such as cardiac or respiratory failure. There are no characteristic findings on physical examination, although some patients have right upper quadrant tenderness. However, physical examination may provide clues toward underlying liver disease, which may have increased the patient's susceptibility to the acute injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic hallmark of ischemic hepatitis is necrosis of hepatocytes in zone 3 of the hepatic acinus associated with a variable degree of architectural collapse around the central vein, depending upon the duration and extent of ischemia. With severe prolonged ischemia, necrosis may extend to the mid zonal hepatocytes. In rare patients, the necrosis may be predominantly mid zonal. There are characteristically few inflammatory cells.",
"   </p>",
"   <p>",
"    There may be coexisting changes reflecting passive congestion, especially in patients with cardiogenic shock. These include sinusoidal engorgement, degeneration and variable degrees of hemorrhagic necrosis in zone 3, fatty change, and variable degrees of cholestasis with occasional bile thrombi in the canaliculi. In patients with chronic or recurrent heart failure, reticulin and collagen accumulate in zone 3, eventually causing fibrous bands to extend outward from the central veins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43013?source=see_link\">",
"     \"Pathogenesis of liver injury in circulatory failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite extensive injury, hepatic architecture may return to normal after recovery from the ischemic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ischemic hepatitis should be aimed at restoring cardiac output and reversing the underlying cause of hemodynamic instability. Overly aggressive diuresis should be avoided since it may worsen hepatic perfusion. Patients should be monitored closely for evidence of end-organ hypoperfusion, particularly decreased renal function and altered mental status.",
"   </p>",
"   <p>",
"    There is no specific therapy for ischemic hepatitis. Limited data suggest that intravenous administration of dopamine, at either \"renal\" or \"cardiac\" doses, leads to preservation, and perhaps augmentation, of hepatic blood flow, but the clinical benefit of such therapy has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/14\">",
"     14",
"    </a>",
"    ]. Whether the effect on hepatic blood flow is due to selective dopaminergic vasodilation of the mesenteric bed or increased cardiac output, or both, is unclear.",
"   </p>",
"   <p>",
"    Similarly, augmentation of cardiac output enhances hepatic perfusion, but the benefit on liver function is uncertain. Thus, the choice of pharmacologic therapy for cardiovascular support should be dictated by the overall hemodynamic condition of the patient, not its potential benefits on hepatic perfusion.",
"   </p>",
"   <p>",
"    Improvement in ischemic hepatitis due to antidepressants following treatment with intravenous N-acetylcysteine was described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/15\">",
"     15",
"    </a>",
"    ]. The mechanism of benefit may have been due to a cytoprotective effect.",
"   </p>",
"   <p>",
"    Reperfusion injury may also influence hepatic recovery. Ongoing research is evaluating methods to reduce such injury in the setting of liver transplantation. However, no specific treatment has been proven to reduce reperfusion injury in patients with ischemic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic hepatitis is nearly always self-limited. The severity of the liver injury correlates with the duration and extent of the hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/16\">",
"     16",
"    </a>",
"    ]. Prognosis is mostly related to the severity of the underlying systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients with ischemic hepatitis that develops in the intensive care unit, on the need for vasopressor therapy or the presence of septic shock, renal failure, or coagulopathy is associated with high mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, serum aminotransferase elevations typically resolve spontaneously over 7 to 10 days in the absence of ongoing hypotension. Normalization of serum bilirubin may be more protracted. A continually rising bilirubin and progressive prolongation of the prothrombin time should raise the suspicion of acute liver failure.",
"   </p>",
"   <p>",
"    Occasional patients develop acute liver failure, usually when ischemic hepatitis is superimposed upon chronic congestive heart failure or in patients with preexisting cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/10\">",
"     10",
"    </a>",
"    ]. Mortality rates ranging from 60 to 100 percent have been described in patients with ischemic hepatitis complicating cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Hepatic decompensation has also been described in previously healthy patients, but the liver injury is usually overshadowed by the underlying condition that led to the liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEPATIC INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic infarction represents focal ischemic injury of the liver and thus should be distinguished from ischemic hepatitis, in which the injury is diffuse. Because the liver has a dual blood supply, hepatic infarction is less common than other forms of ischemic injury. However, the frequency may be increasing because of more widespread use of technologies such as laparoscopic cholecystectomy, hepatic artery chemoembolization and liver transplantation, all of which may result in a focal loss of blood supply to the liver.",
"   </p>",
"   <p>",
"    Hepatic infarction typically results from occlusion of a single intrahepatic branch of the hepatic artery, in contrast to ischemic hepatitis, in which the liver injury is due to a systemic decrease in perfusion or oxygenation. Hepatic artery branches to the right hepatic lobe are affected most commonly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43013?source=see_link\">",
"     \"Pathogenesis of liver injury in circulatory failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many causes of hepatic infarction have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iatrogenic ligation of the hepatic artery (usually the right hepatic artery) has been described most often after laparoscopic cholecystectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombosis of the hepatic artery may be due to atherosclerosis, a hypercoagulable state, or liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Hepatic artery thrombosis following liver transplantation tends to occur at the anastomosis between the native and donor hepatic arteries.",
"     </li>",
"     <li>",
"      Hepatic artery embolization has been reported in patients with infective endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/23\">",
"       23",
"      </a>",
"      ], tumor embolism, or therapeutic embolization or chemoembolization [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatic infarction has been described following radiofrequency ablation of hepatocellular carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other causes include toxemia of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/27\">",
"       27",
"      </a>",
"      ], sickle cell anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/28\">",
"       28",
"      </a>",
"      ], polyarteritis nodosa, hepatic artery aneurysms, cocaine toxicity, and aortic dissection. Hepatic infarction associated with toxemia of pregnancy is notable for its tendency to cause hepatic hemorrhage, which may lead to rupture of Glisson's capsule and catastrophic intraabdominal bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precipitating cause is evident before hepatic infarction develops in many of the clinical settings described above. Hepatic infarction itself may not cause symptoms, but is detected only on an imaging study. Other patients can have moderate to severe features including fever, epigastric or right upper quadrant pain, back or right shoulder pain, jaundice, nausea, and vomiting.",
"   </p>",
"   <p>",
"    A marked leukocytosis is common. The aminotransferases rise transiently, sometimes to massive levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hepatic infarction is suggested radiographically in patients with a compatible clinical history. However, radiographic appearance alone may not be sufficient to distinguish a hepatic infarct from a pyogenic liver abscess or tumor, which can have similar radiographic features. Thus, ultrasound- or computed tomography (CT)-guided needle aspiration of the lesion may be needed to establish a definitive diagnosis. The decision to perform a biopsy should be made based upon the clinical setting, considering such factors as the safety of the biopsy, comorbidities, the probability of a specific diagnosis, and potential concerns related to tumor seeding of the biopsy tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On an abdominal CT scan, a hepatic infarct appears most commonly as a focal, wedge-shaped lesion of low attenuation, which may extend to the capsular surface of the liver. It may also be round or oval-shaped and more centrally located, or irregular and parallel to the intrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The shape may change over time. A hepatic infarct is best seen with intravenous contrast imaging.",
"   </p>",
"   <p>",
"    Some CT characteristics may be helpful in distinguishing an hepatic infarct from a pyogenic liver abscess or tumor. The presence of gas in the lesion is highly suggestive of infection (either a pyogenic liver abscess or a superinfected hepatic infarct), but the absence of gas does not exclude an abscess. Splenic and renal infarcts may be identified radiographically, suggesting an embolic source of the liver findings. Mass lesions, including abscesses and tumors, tend to displace hepatic blood vessels. Thus, nondisplaced blood vessels running through a lesion are suggestive of an infarct rather than an abscess or tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On magnetic resonance imaging, hepatic infarction typically appears as a wedge-shaped region of diminished T1 signal and increased T2 signal, a finding that is relatively nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Doppler ultrasound should be performed to assess the patency of the hepatic artery. Patients who are suspected of having an occluded hepatic artery may require magnetic resonance angiography or occasionally celiac arteriography for confirmation and more detailed localization depending upon the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic histologic findings including a central zone of complete coagulative necrosis involving hepatocytes, portal tracts, and central veins, surrounded by a zone of inflammatory reaction, which is, in turn, surrounded by a zone of partial necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/20\">",
"     20",
"    </a>",
"    ]. The involvement of all three zones of the hepatic acinus is markedly different from the histologic pattern seen in ischemic hepatitis, in which necrosis is confined predominantly to zone 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, no specific therapy for hepatic infarction is required once infection is ruled out. However, it is important to identify potential sources of emboli, such as infective endocarditis or tumor. In the absence of such a source, hypercoagulable states, including proteins C and S or antithrombin deficiency, factor V Leiden mutation, antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria, polycythemia vera, and possibly oral contraceptive use should be considered. Occasional patients with hepatic infarction develop a pyogenic superinfection, which should be suspected if there is persistent worsening of fever, pain, and leukocytosis. Such patients may require aspiration of the lesion to exclude infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further management depends upon the underlying cause of the infarction and its severity. Asymptomatic patients may be managed conservatively. Serial CT scans may show resolution of the infarct over weeks, residual scarring, calcification, or atrophy of the involved lobe of liver. In some patients, anticoagulation is indicated to prevent further systemic emboli or thrombosis. Patients who develop hepatic infarction after liver transplantation often require urgent retransplantation. Hepatic infarction with rupture complicating toxemia of pregnancy requires emergent laparotomy, although in the absence of rupture, expectant management may suffice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ISCHEMIC CHOLANGIOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatic artery (via the peribiliary plexus) provides the exclusive blood supply to the major bile ducts. As a result, compromise of blood flow through the peribiliary plexus may lead to ischemic cholangiopathy, which involves principally the large perihilar intra- and extrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common cause of ischemic cholangiopathy is following liver transplantation; the risk is particularly increased with use of a non-heart beating donor graft [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    .) However, other causes have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/32\">",
"     32",
"    </a>",
"    ] including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vascular injury during biliary tract surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arterial infusion of the chemotherapeutic agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/21/39253?source=see_link\">",
"       floxuridine",
"      </a>",
"      for palliation of liver metastases from gastrointestinal adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chemoembolization and radiation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypercoagulable states leading to occlusion of the peribiliary plexus [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Secondary sclerosing cholangitis in critically ill patients, in whom cirrhosis can develop rapidly and in whom the prognosis is poor [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ischemic cholangiopathy typically present with features suggesting biliary obstruction, such as pruritus, dark urine, clay-colored stools, and jaundice. Liver chemistries reveal a cholestatic pattern with elevations of serum bilirubin and alkaline phosphatase and variable elevations in serum aminotransferase levels. Occasional patients develop ascending cholangitis or cholangitic liver abscesses, with associated fever and right upper quadrant pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic cholangiopathy should be suspected in the clinical settings described above. The main diagnostic challenge is to distinguish it from more common causes of biliary obstruction such as choledocholithiasis and malignancy. The biliary abnormalities may also closely resemble those seen in primary sclerosing cholangitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients require cholangiography performed either by an endoscopic or transhepatic route. Magnetic resonance cholangiopancreatography (MRCP) can also be helpful diagnostically, although it does not permit therapeutic intervention or biopsies to be obtained, both of which may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cholangiographic findings consist of multiple intra- and extrahepatic strictures with diffuse irregularity or beading of the ducts, a more limited number of discrete biliary strictures (usually affecting the large perihilar bile ducts), or disruption of ductal integrity with extravasation of bile and contrast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biopsy is rarely useful and often misleading, because histology reveals only evidence of biliary obstruction, with no indication of the underlying ischemic process. Histologic features of ischemic cholangiopathy (when seen) include ischemic bile duct necrosis, cholangitis without necrosis, biliary casts, and biliary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients found to have a biliary stricture following liver transplantation should undergo a Doppler ultrasound of the hepatic vessels. In questionable cases, arteriography should be performed to rule out hepatic artery thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available regarding the treatment of ischemic cholangiopathy, virtually all related to liver transplantation. Endoscopic therapy with dilation and stenting can be effective for treatment of biliary strictures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    .) Ischemic cholangiopathy occurring within the first month after liver transplantation frequently requires urgent retransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18568/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ischemic hepatitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic hepatitis (also referred to as shock liver, hypoxic hepatitis, and occasionally [and erroneously] acute hepatic infarction) refers to diffuse hepatic injury resulting from acute hypoperfusion. Most patients have no symptoms referable to the liver but have marked elevation of the serum aminotransferase levels after an episode of hypotension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ischemic hepatitis (shock liver, hypoxic hepatitis)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any cause of shock or hemodynamic instability can cause ischemic injury to the liver, although in some reports only approximately one-half of patients with ischemic hepatitis had shock. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic hepatitis should be considered in the clinical settings described above. Few causes of liver injury result in the striking increases in aminotransferase levels (exceeding 1000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or 50 times the upper limit of normal) seen in ischemic hepatitis. Besides ischemic hepatitis, the most common are acute viral hepatitis and acute drug- or toxin-induced liver injury (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      toxicity, certain herbal medications). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic hepatitis is self-limited in most patients. Liver failure is uncommon but more likely in patients with preexisting passive congestion or cirrhosis, or those with sustained hepatic ischemia. Thus, we suggest management be aimed at restoring cardiac output and reversing the underlying cause of hemodynamic instability (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hepatic infarction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compromise of hepatic arterial flow rarely may result in focal hepatic infarction, which must be distinguished from a liver abscess or tumor. Hepatic infarction has been described due to a variety of causes including hepatic arterial thrombosis (especially after liver transplantation), iatrogenic hepatic artery ligation, hepatic artery emboli, vasculitis, aortic dissection, and toxemia of pregnancy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hepatic infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of hepatic infarction is suggested radiographically in patients with a compatible clinical history. However, radiographic appearance alone may not be sufficient to distinguish a hepatic infarct from a pyogenic liver abscess or tumor, which can have similar radiographic features. Thus, ultrasound- or computed tomography-guided needle aspiration of the lesion may be needed to establish a definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As a general rule, no specific therapy for hepatic infarction is required once infection is ruled out. Thus, we suggest supportive treatment only (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, it is important to identify potential sources of emboli, such as infective endocarditis or tumor. In the absence of such a source, hypercoagulable states, including proteins C and S or antithrombin deficiency, factor V Leiden mutation, antiphospholipid syndrome, paroxysmal nocturnal hemoglobinuria, polycythemia vera, and possibly oral contraceptive use should be considered. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ischemic cholangiopathy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic cholangiopathy is observed most commonly after liver transplantation, although several other causes have been reported. Patients typically present with features suggesting biliary obstruction, such as pruritus, dark urine, clay-colored stools, and jaundice. The clinical and cholangiographic features may resemble primary sclerosing cholangitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Ischemic cholangiopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic cholangiopathy should be suspected in the clinical settings described above. The main diagnostic challenge is to distinguish it from more common causes of biliary obstruction such as choledocholithiasis and malignancy. The biliary abnormalities may also closely resemble those seen in primary sclerosing cholangitis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/1\">",
"      Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002; 6:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/2\">",
"      Bynum TE, Boitnott JK, Maddrey WC. Ischemic hepatitis. Dig Dis Sci 1979; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/3\">",
"      Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007; 46:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/4\">",
"      Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/5\">",
"      Henrion J, Minette P, Colin L, et al. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. Hepatology 1999; 29:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/6\">",
"      Gibson PR, Dudley FJ. Ischemic hepatitis: clinical features, diagnosis and prognosis. Aust N Z J Med 1984; 14:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/7\">",
"      Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003; 82:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/8\">",
"      Henrion J, Deltenre P, De Maeght S, et al. Acute lower limb ischemia as a triggering condition in hypoxic hepatitis: a study of five cases. J Clin Gastroenterol 2011; 45:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/9\">",
"      Cohen JA, Kaplan MM. Left-sided heart failure presenting as hepatitis. Gastroenterology 1978; 74:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/10\">",
"      Nouel O, Henrion J, Bernuau J, et al. Fulminant hepatic failure due to transient circulatory failure in patients with chronic heart disease. Dig Dis Sci 1980; 25:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/11\">",
"      Gitlin N, Serio KM. Ischemic hepatitis: widening horizons. Am J Gastroenterol 1992; 87:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/12\">",
"      Fuhrmann V, Madl C, Mueller C, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 2006; 131:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/13\">",
"      Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994; 19:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/14\">",
"      Angehrn W, Schmid E, Althaus F, et al. Effect of dopamine on hepatosplanchnic blood flow. J Cardiovasc Pharmacol 1980; 2:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/15\">",
"      Desai A, Kadleck D, Hufford L, Leikin JB. N-acetylcysteine use in ischemic hepatitis. Am J Ther 2006; 13:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/16\">",
"      Raurich JM, Llompart-Pou JA, Ferreruela M, et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth 2011; 25:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/17\">",
"      Fuhrmann V, Kneidinger N, Herkner H, et al. Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 2011; 37:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/18\">",
"      Henrion J, Colin L, Schmitz A, et al. Ischemic hepatitis in cirrhosis. Rare but lethal. J Clin Gastroenterol 1993; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/19\">",
"      Pauwels A, L&eacute;vy VG. Ischemic hepatitis in cirrhosis: not so rare, not always lethal. J Clin Gastroenterol 1993; 17:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/20\">",
"      Chen V, Hamilton J, Qizilbash A. Hepatic infarction. A clinicopathologic study of seven cases. Arch Pathol Lab Med 1976; 100:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/21\">",
"      Tzakis AG, Gordon RD, Shaw BW Jr, et al. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation 1985; 40:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/22\">",
"      Ludwig J, Gores GJ. Images in clinical medicine. Infarct cavities in a hepatic allograft. N Engl J Med 1995; 333:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/23\">",
"      Henrich WL, Huehnegarth RJ, R&ouml;sch J, Melnyk CS. Gallbladder and liver infarction occurring as a complication of acute bacterial endocarditis. Gastroenterology 1975; 68:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/24\">",
"      Cohen SE, Safadi R, Verstandig A, et al. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig Dis Sci 1997; 42:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/25\">",
"      Chuang CH, Chen CY, Tsai HM. Hepatic infarction and hepatic artery pseudoaneurysm with peritoneal bleeding after radiofrequency ablation for hepatoma. Clin Gastroenterol Hepatol 2005; 3:A23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/26\">",
"      Kim YS, Rhim H, Lim HK, et al. Hepatic infarction after radiofrequency ablation of hepatocellular carcinoma with an internally cooled electrode. J Vasc Interv Radiol 2007; 18:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/27\">",
"      Zissin R, Yaffe D, Fejgin M, et al. Hepatic infarction in preeclampsia as part of the HELLP syndrome: CT appearance. Abdom Imaging 1999; 24:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/28\">",
"      Gauthier N, Cornud F, Vissuzaine C. Liver infarction in sickle cell disease. AJR Am J Roentgenol 1985; 144:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/29\">",
"      Adler DD, Glazer GM, Silver TM. Computed tomography of liver infarction. AJR Am J Roentgenol 1984; 142:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/30\">",
"      Holbert BL, Baron RL, Dodd GD 3rd. Hepatic infarction caused by arterial insufficiency: spectrum and evolution of CT findings. AJR Am J Roentgenol 1996; 166:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/31\">",
"      Fields MS, Desai RK. Hepatic infarction: MRI appearance. Cleve Clin J Med 1991; 58:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/32\">",
"      Deltenre P, Valla DC. Ischemic cholangiopathy. J Hepatol 2006; 44:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/33\">",
"      Cameron AM, Busuttil RW. Ischemic cholangiopathy after liver transplantation. Hepatobiliary Pancreat Dis Int 2005; 4:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/34\">",
"      Terblanche J, Allison HF, Northover JM. An ischemic basis for biliary strictures. Surgery 1983; 94:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/35\">",
"      Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 1989; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/36\">",
"      Cherqui D, Palazzo L, Piedbois P, et al. Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol 1994; 20:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/37\">",
"      Le Thi Huong D, Valla D, Franco D, et al. Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Gastroenterology 1995; 109:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/38\">",
"      Gelbmann CM, R&uuml;mmele P, Wimmer M, et al. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 2007; 102:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/39\">",
"      Ludwig J, Batts KP, MacCarty RL. Ischemic cholangitis in hepatic allografts. Mayo Clin Proc 1992; 67:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18568/abstract/40\">",
"      Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 1993; 17:605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3593 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18568=[""].join("\n");
var outline_f18_8_18568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISCHEMIC HEPATITIS (SHOCK LIVER, HYPOXIC HEPATITIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEPATIC INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ISCHEMIC CHOLANGIOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ischemic hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hepatic infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43701?source=related_link\">",
"      Congestive hepatopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=related_link\">",
"      Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/0/43013?source=related_link\">",
"      Pathogenesis of liver injury in circulatory failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_8_18569="The adrenal incidentaloma";
var content_f18_8_18569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The adrenal incidentaloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Electron Kebebew, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18569/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/8/18569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adrenal incidentaloma is a mass lesion greater than 1 cm in diameter, serendipitously discovered by radiologic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1\">",
"     1",
"    </a>",
"    ]. This entity is the result of technological advances in imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). Discovery of an adrenal mass raises two questions that determine the degree of evaluation and the need for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is it malignant?",
"     </li>",
"     <li>",
"      Is it functioning?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the evaluation and management of adrenal incidentalomas is reviewed here. Detailed discussions of adrenal carcinoma and functioning adrenal tumors such as pheochromocytomas and aldosteronomas are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal masses may be found incidentally when CT scans or MRIs are done for other reasons. In a study of 61,054 abdominal CT scans performed from 1985 to 1990, an incidental adrenal tumor (incidentaloma &gt;1 cm) was detected in 259 patients (0.4 percent of all CT scans) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/3\">",
"     3",
"    </a>",
"    ]. A subsequent study, utilizing higher resolution scanners, reported a prevalence of adrenal incidentaloma on abdominal CT of 4.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/4\">",
"     4",
"    </a>",
"    ]. The prevalence of adrenal incidentaloma is higher in older patients (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In autopsy studies, the prevalence of incidentalomas is 2 percent, and it ranges from 1 to 9 percent. The prevalence is higher in obese, diabetic, and hypertensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, in a series of 739 autopsies, adrenal masses between 2 mm and 4 cm in size were present in 9 percent of normotensive patients and in 12 percent of patients who had hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bilateral masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyses from two large adrenal incidentaloma studies with 887 and 202 patients showed that bilateral masses were found in 10 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Bilateral adrenal masses can be seen with metastatic disease, congenital adrenal hyperplasia, cortical adenomas, lymphoma, infection (eg, tuberculosis, fungal), hemorrhage, ACTH-dependent Cushing's, pheochromocytoma, amyloidosis, infiltrative disease of the adrenal glands, and ACTH-independent bilateral macronodular adrenal hyperplasia. In one study of 208 adrenal incidentaloma patients, 19 (9 percent) proved to have adrenal metastases; 10 of the 19 patients (53 percent) had bilateral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients with bilateral disease, one adrenal mass proves to be a nonfunctioning cortical adenoma while the contralateral adrenal mass is hormone-secreting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, adrenocortical hypofunction may occur in patients with bilateral adrenal masses. Therefore, all patients with bilateral adrenal masses should be screened for adrenocortical hyper- and hypo-function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION FOR MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy is an uncommon cause of adrenal incidentaloma in patients without a known diagnosis of cancer. Although estimates have varied widely, the actual frequency of primary adrenal carcinoma in patients with adrenal incidentaloma is approximately 2 to 5 percent; another 0.7 to 2.5 percent have nonadrenal metastases to the adrenal gland [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1,5,10-12\">",
"     1,5,10-12",
"    </a>",
"    ]. The size and imaging characteristics (\"imaging phenotype\") of the mass may help determine whether the tumor is benign or malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1,11,13\">",
"     1,11,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maximum diameter of the adrenal mass is predictive of malignancy. This was illustrated in a study of 887 patients with adrenal incidentalomas from the National Italian Study Group on Adrenal Tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/7\">",
"     7",
"    </a>",
"    ]. Adrenocortical carcinomas were significantly associated with mass size, with 90 percent being more than 4 cm in diameter when discovered.",
"   </p>",
"   <p>",
"    Adrenal mass size is also important because the smaller the adrenocortical carcinoma is at the time of diagnosis, the better the overall prognosis. In a retrospective review of 62 patients with adrenocortical carcinoma, five-year survival was approximately 16 percent overall, but much higher (42 percent) in patients with smaller tumors (stages I and II, confined to the adrenal gland) who were more likely to undergo curative resection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the report from the National Italian Study Group, a 4 cm cutoff had a 93 percent sensitivity of detecting adrenocortical carcinoma, even though specificity was limited (76 percent of masses larger than 4 cm in diameter were benign) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. In the Mayo Clinic study cited above, all 20 adrenal carcinomas were between 4 and 6 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/3\">",
"     3",
"    </a>",
"    ]. Therefore, surgical removal of unilateral adrenal masses larger than 4 cm should be considered to avoid missing adrenal carcinomas, particularly in younger patients.",
"   </p>",
"   <p>",
"    However, adrenal mass size should not be used as the only parameter to guide treatment. In particular, radiographic characteristics (imaging phenotype) and change in size over time also have strong predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Imaging phenotype'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT or MRI with 2 to 3 mm cuts may allow prediction of the histologic type of the adrenal tumor, which is particularly important in the evaluation of masses that do not meet the size criterion for removal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. As an example, the lipid-rich nature of a cortical adenoma is helpful in distinguishing this benign tumor from carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;On CT scanning, the density of the image (black is less dense) is attributed to x-ray attenuation. The intracytoplasmic fat in adenomas results in low attenuation on nonenhanced CT; nonadenomas have higher attenuation in nonenhanced CT. The Hounsfield scale is a semiquantitative method of measuring x-ray attenuation. Typical precontrast Hounsfield unit (HU) values are adipose tissue = -20 to -150 HU and kidney = 20 to 150 HU. If an adrenal mass measures &lt;10 HU on unenhanced CT (ie, has the density of fat), the likelihood that it is a benign adenoma is nearly 100 percent. However, up to 30 percent of adenomas do not contain large amounts of lipid and may be indistinguishable from nonadenomas on nonenhanced CT scans.",
"   </p>",
"   <p>",
"    A consensus panel noted that a homogeneous adrenal mass with a smooth border and an attenuation value &lt;10 HU on unenhanced CT is very likely to be a benign adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/2\">",
"     2",
"    </a>",
"    ]. This appears to be a reasonable CT HU cutoff based upon a retrospective analysis of 151 patients with adrenal masses who underwent both a noncontrast CT scan and adrenalectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/16\">",
"     16",
"    </a>",
"    ]. The mean HU (&plusmn; SD) for adrenal",
"    <span class=\"nowrap\">",
"     adenomas/hyperplasia",
"    </span>",
"    was significantly lower than for adrenal carcinomas, metastases, and pheochromocytomas (16.2 &plusmn; 13.6 versus 36.9 &plusmn; 4.1, 39.2 &plusmn; 15.2, and 38.6 &plusmn; 8.2, respectively). The only patients in the nonadenoma groups with a noncontrast CT HU &lt;10 were those with myelolipomas (which were all less than -40 and therefore easily distinguishable). In this series, a noncontrast CT HU &le;10 or a combination of tumor size &le;4 cm and HU &le;20 excluded nonadenomas in 100 percent of cases.",
"   </p>",
"   <p>",
"    On delayed contrast-enhanced CT, adenomas typically exhibit rapid contrast medium washout, whereas nonadenomas have delayed contrast material washout [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/16\">",
"     16",
"    </a>",
"    ]. Ten minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent was reported to be 100 percent sensitive and specific for adenoma when patients with adenomas were compared with carcinomas, pheochromocytomas, and metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Although imaging phenotype does not predict hormonal function, it does predict underlying pathology, and surgical resection should be considered in patients with adrenal incidentalomas that have a suspicious imaging phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although CT is the recommended primary adrenal imaging procedure in most cases, MRI has advantages in certain clinical situations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional spin-echo MRI is the most frequently used technique. Using low or mid-field-strength magnets, T1 and T2-weighted imaging can distinguish benign adenomas from malignancy and pheochromocytoma.",
"     </li>",
"     <li>",
"      On gadolinium-DPTA-enhanced MRI, adenomas demonstrate mild enhancement and a rapid washout of contrast, while malignant lesions show rapid and marked enhancement and a slower washout pattern.",
"     </li>",
"     <li>",
"      Chemical shift imaging (CSI) MRI is a form of lipid sensitive imaging based upon the principle that the hydrogen protons in water and lipid molecules resonate at different frequencies, referred to as \"chemical shift\" [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/19\">",
"       19",
"      </a>",
"      ]. Benign adrenal cortical adenomas lose signal on out-of-phase images, but appear relatively bright on in-phase images.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) with either 18-fluoro-2-deoxy-D-glucose (FDG) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/20\">",
"     20",
"    </a>",
"    ] or 11C-metomidate (MTO) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/21\">",
"     21",
"    </a>",
"    ] can be helpful in selected patients (ie, those with a prior history of malignancy or those in which CT densitometry or washout analysis is inconclusive or suspicious for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/5\">",
"     5",
"    </a>",
"    ]) because of their high sensitivity for detecting malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The imaging characteristics of adrenal masses are summarized here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Benign adenomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Round and homogeneous density, smooth contour and sharp margination [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diameter less than 4 cm, unilateral location",
"     </li>",
"     <li>",
"      Low unenhanced CT attenuation values (&lt;10 HU) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52211 \" href=\"UTD.htm?22/28/22977\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rapid contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of more than 50 percent)",
"     </li>",
"     <li>",
"      Isointensity with liver on both T-1 and T-2 weighted MRI sequences",
"     </li>",
"     <li>",
"      Chemical shift evidence of lipid on MRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pheochromocytomas",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased attenuation on nonenhanced CT (&gt;20 HU)",
"     </li>",
"     <li>",
"      Increased mass vascularity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52609 \" href=\"UTD.htm?9/37/9808\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)",
"     </li>",
"     <li>",
"      High signal intensity on T-2 weighted MRI (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75766 \" href=\"UTD.htm?19/13/19664\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cystic and hemorrhagic changes",
"     </li>",
"     <li>",
"      Variable size and may be bilateral",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adrenocortical carcinoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irregular shape",
"     </li>",
"     <li>",
"      Inhomogeneous density because of central areas of low attenuation due to tumor necrosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53633 \" href=\"UTD.htm?40/39/41599\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor calcification",
"     </li>",
"     <li>",
"      Diameter usually &gt;4 cm",
"     </li>",
"     <li>",
"      Unilateral location",
"     </li>",
"     <li>",
"      High unenhanced CT attenuation values (&gt;20 HU)",
"     </li>",
"     <li>",
"      Inhomogeneous enhancement on CT with intravenous contrast",
"     </li>",
"     <li>",
"      Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)",
"     </li>",
"     <li>",
"      Hypointensity compared with liver on T-1 weighted MRI and high to intermediate signal intensity on T-2 weighted MRI",
"     </li>",
"     <li>",
"      High standardized uptake value (SUV) on FDG-PET-CT study",
"     </li>",
"     <li>",
"      Evidence of local invasion or metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adrenal metastases",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irregular shape and inhomogeneous nature",
"     </li>",
"     <li>",
"      Tendency to be bilateral",
"     </li>",
"     <li>",
"      High unenhanced CT attenuation values (&gt;20 HU) and enhancement with intravenous contrast on CT",
"     </li>",
"     <li>",
"      Delay in contrast medium washout (10 minutes after administration of contrast, an absolute contrast medium washout of less than 50 percent)",
"     </li>",
"     <li>",
"      Isointensity or slightly less intense than the liver on T-1 weighted MRI and high to intermediate signal intensity on T-2 weighted MRI (representing an increased water content)",
"     </li>",
"     <li>",
"      Elevated standardized uptake value on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scan",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal cysts, adrenal hemorrhage, and myelolipoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72437 \" href=\"UTD.htm?4/33/4630\">",
"     image 5",
"    </a>",
"    ) are usually easily characterized because of their distinctive imaging characteristics.",
"   </p>",
"   <p>",
"    Despite these radiographic characteristics, currently available imaging studies can be misleading. One study, as an example, evaluated 25 patients with potentially operable non-small cell lung cancer and a unilateral adrenal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/22\">",
"     22",
"    </a>",
"    ]. Thin-section MRI correctly predicted a malignant tumor in all four patients with histologically proven metastases, but 14 of 21 histologically benign masses were read as malignant and two as indeterminate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fine-needle aspiration biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytology from a specimen obtained by fine-needle aspiration (FNA) biopsy",
"    <strong>",
"     cannot",
"    </strong>",
"    distinguish a benign adrenal mass from the less common adrenal carcinoma. It can, however, distinguish between an adrenal tumor and a metastatic tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/23\">",
"     23",
"    </a>",
"    ]. In a patient with a known primary malignancy elsewhere who has a newly discovered adrenal mass that has an imaging phenotype consistent with metastatic disease, performing a diagnostic CT-guided FNA biopsy may be indicated, but only after excluding pheochromocytoma with biochemical testing. Adrenal biopsy would not be needed if the patient was already known to have widespread metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report, as an example, evaluated patients with known lung cancer and an adrenal mass; FNA biopsy revealed a benign adrenal lesion in two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/15\">",
"     15",
"    </a>",
"    ]. When the non-adrenal cancer is occult, most adrenal masses are incidentaloma cortical adenomas (91 of 95 in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/26\">",
"     26",
"    </a>",
"    ]). Thus, FNA biopsy is not useful in the routine evaluation of incidentalomas in patients suspected to have small non-adrenal cancers.",
"   </p>",
"   <p>",
"    Image-guided fine-needle aspiration biopsy is relatively safe; the complication rate was 2.8 percent in one series of 277 biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/27\">",
"     27",
"    </a>",
"    ]. The risks of this procedure include adrenal hematoma, abdominal pain, hematuria, pancreatitis, pneumothorax, formation of an adrenal abscess, and tumor recurrence along the needle track [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The fine-needle aspiration biopsy of a pheochromocytoma may result in hemorrhage and hypertensive crisis. Therefore, the possibility of pheochromocytoma should always be ruled out by biochemical testing before fine-needle aspiration biopsy is undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION FOR HORMONAL SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most adrenal incidentalomas are nonfunctional, 10 to 15 percent secrete excess amounts of hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The most complete analysis of this issue comes from a review of all 828 published articles on adrenal incidentalomas from 1980 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/12\">",
"     12",
"    </a>",
"    ]. Only 20 of the 828 articles were selected as having met the strict criteria for a \"true\" adrenal incidentaloma; of these, only nine had adequate data on both diagnosis and follow-up. Patients who were suspected as having cancer were excluded. Among the 1800 patients in these nine series, these overall mean percentages of diagnoses were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant &ndash; Primary adrenal carcinoma 1.9 percent, metastases 0.7 percent",
"     </li>",
"     <li>",
"      Benign &ndash; Nonfunctioning 89.7 percent, subclinical Cushing&rsquo;s syndrome 6.4 percent, pheochromocytoma 3.1 percent, primary aldosteronism 0.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate case detection tests should be performed if the patient has clinical features that are suggestive of increased adrenal function (",
"    <a class=\"graphic graphic_table graphicRef58753 \" href=\"UTD.htm?2/18/2348\">",
"     table 1",
"    </a>",
"    ). However, subclinical Cushing's syndrome and pheochromocytoma are sufficiently common that",
"    <strong>",
"     all",
"    </strong>",
"    patients with an adrenal incidentaloma should be tested for these disorders. In addition, hypertensive patients should be evaluated for an aldosteronoma even if the serum potassium concentration is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Subclinical Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subclinical Cushing's syndrome (ie, glucocorticoid secretory autonomy without clinical manifestations of Cushing's syndrome) is the most frequent hormonal abnormality detected in patients with adrenal incidentalomas. Some adrenal incidentalomas secrete cortisol independently of ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/31\">",
"     31",
"    </a>",
"    ], which may have clinically important consequences. In addition, cortisol secretion can be under the control of one or more aberrant hormone receptors in patients with unilateral adenomas or incidental bilateral ACTH-independent macronodular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link&amp;anchor=H5#H5\">",
"     \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\", section on 'Aberrant hormone receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these patients lack many of the usual stigmata of overt Cushing's syndrome, they may have one or more of the effects of continuous ACTH-independent cortisol secretion, including hypertension, diabetes, and a high incidence of vertebral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/34\">",
"     34",
"    </a>",
"    ]. Those with subclinical Cushing's syndrome are more likely to have hypertension, dyslipidemia, impaired glucose tolerance or type 2 diabetes mellitus, and evidence of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a two-year longitudinal study of 103 consecutive patients with adrenal incidentaloma, the incidence of new vertebral fractures was higher in the group with subclinical Cushing&rsquo;s syndrome (48 percent) than the adrenal incidentaloma group without subclinical Cushing&rsquo;s (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one large series of adrenal incidentalomas, hormonal evaluation in the patients with subclinical Cushing's syndrome showed the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low baseline secretion of corticotropin (ACTH) in 79 percent",
"     </li>",
"     <li>",
"      Lack of suppressibility of cortisol secretion after 1 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      in 73 percent",
"     </li>",
"     <li>",
"      Supranormal 24-hour urinary cortisol excretion in 75 percent",
"     </li>",
"     <li>",
"      Disturbed cortisol circadian rhythm in 43 percent",
"     </li>",
"     <li>",
"      Blunted plasma ACTH responses to corticotropin-releasing hormone in 55 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of a lack of sensitivity of most corticotropin (ACTH) assays at the lower part of the reference range, most centers rely on an alternate measure of autonomous cortisol secretion: the overnight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test (DST). Some centers use a higher dose of dexamethasone (eg, 3 mg rather than the standard 1 mg) to reduce false positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/37\">",
"     37",
"    </a>",
"    ], and others use a lower cortisol cutoff (eg, &gt;2.2",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [&gt;60",
"    <span class=\"nowrap\">",
"     nmol/L]",
"    </span>",
"    or 1.8",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [50",
"    <span class=\"nowrap\">",
"     nmol/L]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/38\">",
"     38",
"    </a>",
"    ] rather than &gt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [&gt;138",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    to reduce false negative results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of the two-day low-dose DST [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/40\">",
"     40",
"    </a>",
"    ] showed a gradation between subnormal and complete suppression of serum cortisol concentrations in 57 patients with adrenal incidentalomas (21 percent had undetectable serum levels of cortisol, 67 percent had values between 1 and 5",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    and 12 percent had values between 5.0 and 7.8",
"    <span class=\"nowrap\">",
"     mcg/dL).",
"    </span>",
"    Thus, the question for the clinician should not be whether the cortical adenoma has glucocorticoid secretory activity. The question is whether the cortical adenoma has",
"    <strong>",
"     clinically significant",
"    </strong>",
"    glucocorticoid secretory activity. It is for this reason that many clinicians prefer to keep the 1 mg DST cortisol cutoff at &gt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (&gt;138",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the post-overnight DST 8 AM serum cortisol concentration is abnormal, then additional tests should be considered to confirm glucocorticoid excess. Dehydroepiandrosterone-sulfate (DHEA-S) is an adrenal androgen produced under the stimulation of ACTH. Thus, an undetectable serum concentration of DHEA-S suggests chronic suppression of ACTH. An undetectable level of serum ACTH is also supportive of the diagnosis of subclinical Cushing&rsquo;s syndrome. Additional tests to consider when confirming glucocorticoid secretory autonomy include diurnal serum cortisol, baseline 24-hour cortisol excretion, and high-dose (8 mg) overnight DST.",
"   </p>",
"   <p>",
"    Should all patients with subclinical Cushing's syndrome undergo unilateral adrenalectomy? In the absence of a prospective randomized study, it is reasonable to consider that younger patients and those who have disorders potentially attributable to excess glucocorticoid secretion (eg, recent onset of hypertension, diabetes, obesity, and low bone mass) and have well-documented glucocorticoid secretory autonomy (eg, suppressed DHEA-S, low serum ACTH concentration, lack of suppression to high-dose overnight DST [8 AM serum cortisol &gt;5",
"    <span class=\"nowrap\">",
"     mcg/dL])",
"    </span>",
"    are candidates for adrenalectomy. If adrenalectomy is performed, perioperative glucocorticoid coverage should be administered because of the risk of adrenal insufficiency, hemodynamic crisis, and death. Weight loss, improvement in hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glycemic control, and normalization of markers of bone turnover are frequently found following unilateral adrenalectomy in patients with subclinical Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 percent of adrenal incidentalomas prove to be pheochromocytomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/12\">",
"     12",
"    </a>",
"    ]. In the past, it was thought that all patients with pheochromocytoma are symptomatic. However, with widespread use of computed imaging, pheochromocytomas are being discovered in the presymptomatic stage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Although some recommend measurement of plasma fractionated metanephrines in all patients with adrenal incidentaloma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/2\">",
"     2",
"    </a>",
"    ], we suggest this measurement only when the pre-test probability of pheochromocytoma is high (eg, if the mass is vascular, dense, and has slow contrast washout), because while this test is very sensitive (95 to 98 percent), it is not very specific (89 to 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/12,45,46\">",
"     12,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with adrenal masses that, based on imaging phenotype, have a low probability for pheochromocytoma (eg, the adrenal mass is hypodense with rapid contrast washout), we suggest routine measurement of 24-hour urinary fractionated metanephrines and catecholamines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Aldosteronomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosteronomas are rare (less than 1 percent) causes of an adrenal incidentaloma. However, because the majority of patients with primary aldosteronism are not hypokalemic, all patients with hypertension and an adrenal incidentaloma should be evaluated by measurements of plasma aldosterone concentration and plasma renin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Unilateral adrenal masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with documented pheochromocytoma and adrenocortical cancer should undergo prompt surgical intervention because untreated pheochromocytoma may result in significant cardiovascular complications. Alpha blockade should be given before patients undergo adrenalectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with adrenocortical cancer or lesions suspicious for adrenocortical cancer should also undergo prompt adrenalectomy as their disease may progress rapidly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=see_link\">",
"     \"Treatment of adrenocortical carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with aldosterone-producing adenomas should be offered surgery to cure aldosterone excess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .) Some patients with documented subclinical Cushing's syndrome should be selected for surgery based upon the clinical parameters discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the treatment of Cushing's syndrome\", section on 'Primary adrenal diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adrenal masses with either suspicious imaging phenotype or size larger than 4 cm should be considered for resection because a substantial fraction will be adrenocortical carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. The clinical scenario and patient age frequently guide the management decisions in patients who have adrenal incidentalomas that fall on either side of the 4 cm diameter cutoff. As an example, most clinicians would advise resecting a uniform hypodense (9 HU) 3.7 cm adrenal incidentaloma in a 23-year-old woman, whereas most clinicians would choose serial imaging follow-up in an 83-year-old woman with a uniform hypodense (9 HU) 4.7 cm adrenal incidentaloma. Surgical resection should be considered in this example of a young woman because adrenal cortical nodularity is, in part, a function of aging and such a finding in a 23-year-old is not normal. In addition, the alternative would be long-term imaging follow-up, which is associated with clinically significant expense, worry, and risks. Before surgery, all patients should undergo appropriate testing for functional tumors. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Evaluation for hormonal secretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adrenal myelolipoma is a benign tumor composed of mature fat and interspersed hematopoietic elements that resemble bone marrow. On computed imaging, the presence of large amounts of macroscopic fat in an adrenal mass is diagnostic of a myelolipoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72437 \" href=\"UTD.htm?4/33/4630\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/48\">",
"     48",
"    </a>",
"    ]. Although adrenal myelolipomas may grow over time, they can usually be followed without surgical excision. However, when larger than 6 cm in diameter or when causing local mass-effect symptoms, surgical removal should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bilateral adrenal masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of bilateral adrenal masses is different from that for unilateral masses. As an example, in cases of subclinical ACTH-independent bilateral macronodular adrenal hyperplasia, size is not an indication for surgery, as some can be as large as 5 to 10 cm with insufficient hormone production to necessitate surgery. Patients with bilateral adrenal masses should be investigated for congenital adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Adrenalectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenalectomy for patients with aldosteronomas, pheochromocytoma, cortisol-secreting tumors, and adrenal incidentalomas is safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/50\">",
"     50",
"    </a>",
"    ]. An adrenalectomy may be done laparoscopically, endoscopically via the posterior approach, or as an open procedure. Laparoscopic adrenalectomy, compared with open adrenalectomy, is associated with less pain, shorter hospitalization time, less blood loss, and faster recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/51\">",
"     51",
"    </a>",
"    ]. The laparoscopic approach is used for most adrenal masses.",
"   </p>",
"   <p>",
"    In patients with known or suspected adrenal carcinoma, the laparoscopic approach should only be considered if the adrenal mass is &lt;10 cm and does not appear to be locally invasive [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. An open adrenalectomy is recommended for all large (&gt;10 cm) adrenal masses, including those benign imaging features, as the adrenal mass may be diagnosed as malignant on a definitive histologic review [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/52,54-57\">",
"     52,54-57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Imaging phenotype'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;For incidentalomas with a benign appearance on imaging, repeat imaging after three to six months should be performed to reevaluate for possible malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/5\">",
"     5",
"    </a>",
"    ]. The decision to obtain additional images (eg, at 6, 12, and 24 months after the initial image) and the type of image obtained (eg, CT or MRI) should be guided by the individual clinical circumstance, imaging phenotype, and clinical judgment.",
"   </p>",
"   <p>",
"    As an example, a single repeat image is reasonable in patients who have no history of malignancy and who have small (less than 2 cm), uniform, hypodense, cortical nodules (ie, benign imaging phenotype). There are no prospective studies of the optimal frequency and duration of follow-up for adrenal incidentalomas. In addition, the radiation exposure related to CT should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link&amp;anchor=H244336#H244336\">",
"     \"Radiation-related risks of imaging studies\", section on 'Clinical decision-making and informing patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most experts would consider resecting any tumor that enlarges by more than 1 cm in diameter during the follow-up period. However, most adrenal masses that grow are not malignant.",
"   </p>",
"   <p>",
"    The observation that autonomous function (glucocorticoid and catecholamine) not present at baseline may be detected at follow-up testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/58-60\">",
"     58-60",
"    </a>",
"    ] has led to the recommendation for repeating hormonal evaluation annually for four years in cases where initial evaluation is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/1,59,60\">",
"     1,59,60",
"    </a>",
"    ]; however, the yield and cost effectiveness of such testing is also unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18569/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/53/851?source=see_link\">",
"       \"Patient information: Adrenal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with adrenal incidentalomas should be evaluated for the possibility of subclinical hormonal hyperfunction and cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough history and physical examination are important in the initial assessment.",
"     </li>",
"     <li>",
"      A homogeneous adrenal mass &lt;4 cm in diameter, with a smooth border, and an attenuation value &lt;10 HU on unenhanced CT, and rapid contrast medium washout (eg, &gt;50 percent at 10 minutes) is very likely to be a benign cortical adenoma.",
"     </li>",
"     <li>",
"      The imaging characteristics that suggest adrenal carcinoma or metastases include: irregular shape, inhomogeneous density, high unenhanced CT attenuation values (&gt;20 HU), delayed contrast medium washout (eg, &lt;50 percent at 10 minutes), diameter &gt;4 cm, and tumor calcification. Other characteristics are described above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adrenocortical carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pheochromocytoma should be excluded in all patients by measuring 24-hour urinary fractionated metanephrines and catecholamines. If the adrenal mass is vascular, or there are other features suggestive of pheochromocytoma, the preferred test is plasma fractionated metanephrines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subclinical Cushing's syndrome should be ruled out by performing the 1 mg overnight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression test. To detect",
"      <strong>",
"       clinically significant",
"      </strong>",
"      glucocorticoid secretory autonomy, the post-overnight DST 8 AM serum cortisol concentration cutoff is &gt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (&gt;138",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      An abnormal 1 mg overnight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression is consistent with ACTH-independent cortisol production, a finding that should be confirmed with 24-hour urinary free cortisol, serum ACTH concentration, DHEA-S, and a high-dose dexamethasone suppression test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"       \"Establishing the diagnosis of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the adrenal incidentaloma patient is hypertensive, a plasma aldosterone-to-plasma renin activity ratio and plasma potassium concentration should be obtained to screen for primary aldosteronism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"       \"Approach to the patient with hypertension and hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend surgery for all patients with biochemical documentation of pheochromocytoma (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The preoperative management of patients with pheochromocytoma is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of pheochromocytoma in adults\", section on 'Medical preparation for surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest a surgical resection for patients with subclinical Cushing's syndrome who are younger and who have disorders potentially attributable to excess glucocorticoid secretion (eg, recent onset of hypertension, diabetes, obesity, and low bone mass) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest a surgical resection for patients with adrenal masses greater than 4 cm in diameter (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the clinical scenario, imaging characteristics, and patient age frequently guide the management decisions in patients who have adrenal incidentalomas that fall on either side of the 4 cm diameter cutoff. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Unilateral adrenal masses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with a known primary malignancy elsewhere who has a newly discovered adrenal mass that has an imaging phenotype consistent with metastatic disease, performing a diagnostic CT-guided FNA biopsy may be indicated, but only after excluding pheochromocytoma with biochemical testing. Adrenal biopsy would not be needed if the patient was already known to have widespread metastatic disease.",
"     </li>",
"     <li>",
"      We recommend excision of a tumor if the initial imaging phenotype is suspicious (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For all adrenal masses larger than 10 cm, including those masses with benign imaging phenotypes, we recommend an open adrenalectomy rather than a laparoscopic procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Adrenalectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a repeat imaging study at three to six months after initial discovery (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The rationale is that many malignant lesions will grow in this interval, leading to earlier intervention. Whether to obtain additional images (eg, at 6, 12, and 24 months after initial discovery) and the type of image obtained (eg, CT, MRI, or ultrasound) should be guided by clinical judgment and imaging phenotype. The yield and cost-effectiveness of such a strategy are not known. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest removal of any tumor that enlarges by more than 1 cm in diameter during the follow-up period (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that hormonal testing be repeated annually for four years in cases where initial evaluation is negative, although the yield and cost-effectiveness of such testing is also unknown. However, autonomous function (glucocorticoid) not present at baseline may be detected at follow-up testing.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/1\">",
"      Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/2\">",
"      Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (\"incidentaloma\"). Ann Intern Med 2003; 138:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/3\">",
"      Herrera MF, Grant CS, van Heerden JA, et al. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991; 110:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/4\">",
"      Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006; 29:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/5\">",
"      Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/6\">",
"      Hedeland H, Ostberg G, H&ouml;kfelt B. On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968; 184:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/7\">",
"      Angeli A, Osella G, Al&igrave; A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997; 47:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/8\">",
"      Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 1998; 83:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/9\">",
"      Kasperlik-Zeluska AA, Rosonowska E, Sowinska-Srzednicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 1997; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/10\">",
"      Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000; 29:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/11\">",
"      Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/12\">",
"      Cawood TJ, Hunt PJ, O'Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009; 161:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/13\">",
"      Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 2010; 95:4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/14\">",
"      Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma--a continuing challenge. Surgery 1983; 94:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/15\">",
"      Dunnick NR, Korobkin M, Francis I. Adrenal radiology: distinguishing benign from malignant adrenal masses. AJR Am J Roentgenol 1996; 167:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/16\">",
"      Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005; 90:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/17\">",
"      Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/18\">",
"      Pe&ntilde;a CS, Boland GW, Hahn PF, et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/19\">",
"      Israel GM, Korobkin M, Wang C, et al. Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol 2004; 183:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/20\">",
"      Groussin L, Bonardel G, Silv&eacute;ra S, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 2009; 94:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/21\">",
"      Hennings J, Hellman P, Ahlstr&ouml;m H, Sundin A. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 2009; 69:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/22\">",
"      Burt M, Heelan RT, Coit D, et al. Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. Impact of magnetic resonance imaging. J Thorac Cardiovasc Surg 1994; 107:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/23\">",
"      Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg 2009; 144:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/24\">",
"      Cook DM, Loriaux DL. The incidental adrenal mass. Am J Med 1996; 101:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/25\">",
"      Jhala NC, Jhala D, Eloubeidi MA, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: analysis of 24 patients. Cancer 2004; 102:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/26\">",
"      Lee JE, Evans DB, Hickey RC, et al. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 1998; 124:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/27\">",
"      Welch TJ, Sheedy PF 2nd, Stephens DH, et al. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 1994; 193:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/28\">",
"      Arellano RS, Harisinghani MG, Gervais DA, et al. Image-guided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol 2003; 32:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/29\">",
"      Casola G, Nicolet V, vanSonnenberg E, et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology 1986; 159:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/30\">",
"      McCorkell SJ, Niles NL. Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistake. AJR Am J Roentgenol 1985; 145:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/31\">",
"      Tauchmanov&agrave; L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87:4872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/32\">",
"      Reznik Y, Lefebvre H, Rohmer V, et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol (Oxf) 2004; 61:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/33\">",
"      Hsiao HP, Kirschner LS, Bourdeau I, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009; 94:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/34\">",
"      Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 2009; 94:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/35\">",
"      Sereg M, Szappanos A, Toke J, et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur J Endocrinol 2009; 160:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/36\">",
"      Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/37\">",
"      Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am 2000; 29:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/38\">",
"      Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/39\">",
"      Valli N, Catargi B, Ronci N, et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol 2001; 144:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/40\">",
"      Tsagarakis S, Kokkoris P, Roboti C, et al. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 48:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/41\">",
"      Mantero F, Arnaldi G. Investigation protocol: adrenal enlargement. Clin Endocrinol (Oxf) 1999; 50:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/42\">",
"      Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 2003; 50:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/43\">",
"      Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol 2005; 185:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/44\">",
"      Kopetschke R, Slisko M, Kilisli A, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol 2009; 161:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/45\">",
"      Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/46\">",
"      Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/47\">",
"      Toniato A, Merante-Boschin I, Opocher G, et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009; 249:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/48\">",
"      Craig WD, Fanburg-Smith JC, Henry LR, et al. Fat-containing lesions of the retroperitoneum: radiologic-pathologic correlation. Radiographics 2009; 29:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/49\">",
"      Mermejo LM, Elias Junior J, Saggioro FP, et al. Giant adrenal myelolipoma associated with 21-hydroxylase deficiency: unusual association mimicking an androgen-secreting adrenocortical carcinoma. Arq Bras Endocrinol Metabol 2010; 54:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/50\">",
"      Liao CH, Lai MK, Li HY, et al. Laparoscopic adrenalectomy using needlescopic instruments for adrenal tumors less than 5cm in 112 cases. Eur Urol 2008; 54:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/51\">",
"      Thompson GB, Grant CS, van Heerden JA, et al. Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 1997; 122:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/52\">",
"      Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005; 138:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/53\">",
"      Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004; 5:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/54\">",
"      Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/55\">",
"      Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/56\">",
"      Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 2010; 162:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/57\">",
"      Miller BS, Ammori JB, Gauger PG, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010; 34:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/58\">",
"      Lib&egrave; R, Dall'Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002; 147:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/59\">",
"      B&uuml;low B, Jansson S, Juhlin C, et al. Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur J Endocrinol 2006; 154:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18569/abstract/60\">",
"      Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999; 84:520.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 153 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-B32189B1BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18569=[""].join("\n");
var outline_f18_8_18569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bilateral masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION FOR MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging phenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Benign adenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pheochromocytomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adrenal metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fine-needle aspiration biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION FOR HORMONAL SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Subclinical Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Aldosteronomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Unilateral adrenal masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bilateral adrenal masses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/153|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/28/22977\" title=\"diagnostic image 1\">",
"      Adrenal adenoma hypodense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/37/9808\" title=\"diagnostic image 2\">",
"      Pheochromocytoma silent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/13/19664\" title=\"diagnostic image 3\">",
"      MRI of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/39/41599\" title=\"diagnostic image 4\">",
"      Adrenal cancer CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/33/4630\" title=\"diagnostic image 5\">",
"      Adrenal myelolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/18/2348\" title=\"table 1\">",
"      Screening adrenal indcidentaloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/53/851?source=related_link\">",
"      Patient information: Adrenal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40762?source=related_link\">",
"      Treatment of adrenocortical carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_8_18570="Pathophysiology and management of fever in infants and children";
var content_f18_8_18570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and management of fever in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18570/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18570/contributors\">",
"     Mark A Ward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18570/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/8/18570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/8/18570/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/8/18570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is an abnormal elevation of body temperature that occurs as part of a specific biologic response that is mediated and controlled by the central nervous system. &nbsp;",
"   </p>",
"   <p>",
"    The pathophysiology and treatment of fever in infants and children will be reviewed here. Other causes of elevated body temperature in children and the evaluation and management of fever in specific populations of infants and children are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link\">",
"       \"Heat stroke in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link\">",
"       \"Heat illness (other than heat stroke) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=see_link\">",
"       \"Management of fever in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"       \"Etiologies of fever of unknown origin in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"       \"Approach to the child with fever of unknown origin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"       \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"       \"Fever in children with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19255?source=see_link\">",
"       \"Fever in human immunodeficiency virus-infected infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703490142\">",
"    <span class=\"h1\">",
"     TEMPERATURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites of temperature measurement in clinical practice are the rectum, mouth, and axilla; in addition, parents and caregivers may measure temperature at the tympanic membrane or forehead (temporal artery). Each of these sites has its own range of normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Opinions differ about the best site of temperature measurement for young children who cannot cooperate with oral thermometry. The Bright Futures Guidelines for Health Supervision suggest rectal thermometry for children younger than four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, the National Institute for Clinical Excellence recommends electronic axillary thermometry for children younger than four weeks, and axillary (electronic or chemical dot) or infra-red tympanic membrane thermometry for children four weeks to five years of age because these methods are quicker, easier to use, and better accepted by children and their caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rectal thermometry is generally considered the gold standard for measurement of core body temperature, but there is a lag between changes in core body temperature and temperature in the rectal vault [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/4\">",
"     4",
"    </a>",
"    ]. Rectal thermometry is usually performed in infants and young children if the result has clinical implications. The majority of studies establishing the risk of serious infections in febrile infants and young children have relied on rectal temperatures. Rectal thermometry is contraindicated in patients with neutropenia.",
"   </p>",
"   <p>",
"    Oral thermometry generally is preferred in children who are old enough to cooperate. Oral temperature is typically 0.6&ordm;C (1.0&ordm;F) lower than rectal temperature because of mouth breathing, which is particularly important in patients with tachypnea. Oral temperatures also may be affected by recent ingestion of hot or cold liquids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Axillary temperature is consistently lower than rectal temperature, but the absolute difference varies too widely for a standard conversion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/6\">",
"     6",
"    </a>",
"    ]. Axillary temperatures may be measured in neutropenic patients who are unable to use an oral thermometer.",
"   </p>",
"   <p>",
"    Infrared tympanic membrane (TM) thermometers measure the amount of heat produced by the tympanic membrane. Temperature readings are close to core temperature, although the infrared TM reflective devices commonly used in homes, hospitals, and offices are considerably less accurate than TM thermistors used in research and by anesthesiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/4,7-15\">",
"     4,7-15",
"    </a>",
"    ]. Individual studies comparing TM and rectal temperatures in children have had contradictory results. A systematic review concluded that TM thermometry shows insufficient agreement with established methods of core temperature measurement to be used in situations where detection of fever has clinical implications (eg, laboratory evaluation of the febrile neonate or young infant) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infrared skin thermometers measure the amount of heat produced by the temporal arteries. The accuracy of such measurements may be affected by sweating or vascular changes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1\">",
"     1",
"    </a>",
"    ]. As with tympanic temperature measurement, studies comparing temporal and rectal temperatures have contradictory results, and temporal temperatures should not be used to make clinical decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/4,17-25\">",
"     4,17-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703490149\">",
"    <span class=\"h2\">",
"     Converting between Fahrenheit and Celsius",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fahrenheit and Celsius temperature equivalents are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef73846 \" href=\"UTD.htm?34/36/35405\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To convert a temperature measured in Fahrenheit to Celsius:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (Temperature in &deg;F &ndash; 32) x",
"      <span class=\"nowrap\">",
"       (5/9)",
"      </span>",
"      = Temperature in &deg;C",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To convert a temperature measured in Celsius to Fahrenheit:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       [(9/5)",
"      </span>",
"      x Temperature in &deg;C] + 32 = Temperature in &deg;F",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48346114\">",
"    <span class=\"h1\">",
"     TEMPERATURE HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body temperature is controlled by the thermoregulatory center of the hypothalamus. The thermoregulatory center balances heat production, derived primarily from metabolic activity in muscle and the liver, with heat dissipation from the skin and lungs. The thermoregulatory center is able to maintain a fairly steady body temperature in normal temperature environments. However, at environmental temperatures higher than approximately 35&deg;C (95&deg;F), the body&rsquo;s ability to dissipate heat is overwhelmed, and core temperature rises. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H4#H4\">",
"     \"Heat stroke in children\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL BODY TEMPERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean normal temperature is generally considered to be 37&ordm;C (98.6&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/26\">",
"     26",
"    </a>",
"    ]. This value usually is attributed to studies dating to the 19",
"    <sup>",
"     th",
"    </sup>",
"    century. In a more recent study of young adults, the upper limit of normal body temperature (measured orally) was 37.2&ordm;C (98.9&ordm;F) in the morning and 37.7&ordm;C (99.9&ordm;F) overall [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/27\">",
"     27",
"    </a>",
"    ]. Normal body temperature varies with age, time of the day, level of activity, and phase of the menstrual cycle, among other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants and young children generally have higher temperatures than older children and adults. This relates to the greater surface-area-to-body-weight ratio and the higher metabolic rate of infants and small children. In the newborn period (age 0 to 28 days), the mean normal temperature (measured rectally) is 37.5&deg;C, with an upper limit of normal (ie, two standard deviations above the mean) of 38&ordm;C (100.4&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal temperature varies daily, with a morning nadir and late",
"    <span class=\"nowrap\">",
"     afternoon/early",
"    </span>",
"    evening peak. The mean amplitude of variation is 0.5&ordm;C (0.9&ordm;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/27\">",
"     27",
"    </a>",
"    ]. During a febrile illness, daily low and high temperature readings are maintained, but at higher-than-normal levels. Daily variation can be as high as 1&ordm;C in some individuals recovering from a febrile illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10722181\">",
"    <span class=\"h1\">",
"     ELEVATED BODY TEMPERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated body temperature may result from fever (increased body temperature with elevated hypothalamic set-point) or hyperthermia (increased body temperature with normal hypothalamic set-point) (",
"    <a class=\"graphic graphic_figure graphicRef58558 \" href=\"UTD.htm?32/23/33149\">",
"     figure 1",
"    </a>",
"    ). It is important to differentiate between these conditions because they have different clinical implications and management strategies. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Management of fever'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H16#H16\">",
"     \"Heat stroke in children\", section on 'Hospital management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70202186\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is an abnormal elevation of body temperature that occurs as part of a specific biologic response that is mediated and controlled by the central nervous system. (See",
"    <a class=\"local\" href=\"#H48346159\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The temperature elevation that is considered &ldquo;abnormal&rdquo; depends upon the age of the child and the site of measurement. The temperature elevation that may prompt clinical investigation for infection depends upon the age of the child and the clinical circumstances (eg, immune deficiency, sickle cell disease, ill-appearance, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the otherwise healthy neonate (0 to 28 to 30 days of age), fever of concern generally is defined by rectal temperature &ge;38.0&ordm;C (100.4&ordm;F). In the otherwise healthy one- to three-month-old, fever of concern generally is defined by rectal temperature &ge;38.0 to 38.2&ordm;C (100.4 to 100.7&ordm;F). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link&amp;anchor=H2#H2\">",
"       \"Definition and etiology of fever in neonates and infants (less than three months of age)\", section on 'Definition of fever'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      In children 3 to 36 months, fever generally is defined by rectal temperatures ranging from &ge;38.0 to 39.0&ordm;C (100.4 to 102.2&ordm;F) and of concern by rectal temperatures &ge;39.0&ordm;C (102.2&ordm;F). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link&amp;anchor=H3#H3\">",
"       \"Fever without a source in children 3 to 36 months of age\", section on 'Fever of concern'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In older children and adults, fever may be defined by oral temperatures ranging from &ge;37.8 to 39.4&ordm;C (100.0 to 103.0&ordm;F) and fever of concern by oral temperatures &ge;39.5&ordm;C (103.1&ordm;F).",
"     </li>",
"     <li>",
"      The temperature thresholds of concern for children with underlying conditions (eg, sickle cell disease, neutropenia, HIV) are discussed separately. (See appropriate topic reviews.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48346159\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is the result of a highly coordinated series of events that begins peripherally with the synthesis and release of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), interferon (IFN)-alpha, and other endogenous pyrogenic cytokines by phagocytic cells in the blood or tissues (",
"    <a class=\"graphic graphic_algorithm graphicRef80455 \" href=\"UTD.htm?29/42/30382\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/33\">",
"     33",
"    </a>",
"    ]. These cytokines enter the blood and are carried to the anterior hypothalamus, where they induce an abrupt increase in the synthesis of prostaglandins, especially prostaglandin E2 (PGE2). The induction of PGE2 in the brain raises the hypothalamic set-point for body temperature (",
"    <a class=\"graphic graphic_figure graphicRef58558 \" href=\"UTD.htm?32/23/33149\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After the set-point is raised, the thermoregulatory center recognizes current body temperature to be too low and initiates a series of events to raise body temperature to the new set-point. This involves augmentation of heat production by increased metabolic rate and increased muscle tone and activity, and decreased heat loss through diminished perfusion of the skin. Body temperature rises until a new equilibrium is achieved at the elevated set-point. The upper limit of temperature due to fever appears to be 42&ordm;C (107.6&ordm;F), but it is unusual for temperature to exceed 41&ordm;C (106&ordm;F) without some element of concomitant hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,34,35\">",
"     1,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to causing fever, pyrogenic cytokines increase the synthesis of acute-phase proteins by the liver, decrease serum iron and zinc levels, provoke leukocytosis, and accelerate skeletal muscle proteolysis. IL-1 also induces slow-wave sleep, perhaps explaining the somnolence frequently associated with febrile illnesses. The increase in peripheral PGE2 may account for the myalgias and arthralgias that often accompany fever. Increased heart rate is a normal physiologic response to fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48346430\">",
"    <span class=\"h3\">",
"     Benefits and harms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether fever is beneficial or harmful is disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/35\">",
"     35",
"    </a>",
"    ]. Fever is an integral part of the inflammatory response and, as such, may have a role in fighting infection. However, defense mechanisms can go awry. Even if fever does have a role in defending the host against infection, it may still be that, in some circumstances, fever does more harm than good [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Potential benefits",
"      </strong>",
"      &ndash; Potential benefits of fever include retardation of the growth and reproduction of some bacteria and viruses (perhaps related to decreased serum iron) and enhanced immunologic function at moderately elevated temperatures (although some of the benefits are reversed at temperatures approaching 40&ordm;C [104&ordm;F]) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/35,38-43\">",
"       35,38-43",
"      </a>",
"      ]. Some animal studies have demonstrated enhanced survival with fever [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. However, as with immune function, the benefits may be diminished or even reversed as temperature increases [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Whether these findings apply to humans is not known.",
"     </li>",
"     <li>",
"      <strong>",
"       Potential harms",
"      </strong>",
"      &ndash; Fever can make patients uncomfortable. It is associated with increased metabolic rate, oxygen consumption, carbon dioxide production, and demands on the cardiovascular and pulmonary systems. For the normal child, these stresses are of little or no consequence. However, for the child in shock or for the child with a pulmonary or cardiac abnormality, the increased demands can be detrimental and may offset any immunologic benefit from the fever.",
"      <br/>",
"      <br/>",
"      In experimental studies, fever has been associated with impaired immunologic responses (eg, phagocytosis of staphylococci and lymphocyte transformation in response to mitogens) and cerebral injury (including edema and hemorrhage) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. Whether these findings apply to humans is not known.",
"      <br/>",
"      <br/>",
"      There is no evidence to suggest that fever &ge;40&ordm;C (104&ordm;F) is associated with increased risk of adverse outcome (eg, brain damage) although this belief is held by many caregivers and clinicians [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38,50,51\">",
"       38,50,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70202193\">",
"    <span class=\"h2\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthermia is an abnormal elevation of body temperature that occurs without a change in the thermoregulatory set point in the hypothalamus (",
"    <a class=\"graphic graphic_figure graphicRef58558 \" href=\"UTD.htm?32/23/33149\">",
"     figure 1",
"    </a>",
"    ). This failure of normal homeostasis results in heat production that exceeds the body&rsquo;s capacity for dissipation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristic clinical features of hyperthermia include a history of environmental heat exposure or use of drugs that interfere with normal thermoregulation (eg, anticholinergics); hot, dry skin; and central nervous system dysfunction (eg, delirium, convulsions, coma). Hyperthermia can be rapidly fatal; adverse physiologic effects begin to occur at temperatures &gt;41&deg;C (105.8&deg;F). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H9#H9\">",
"     \"Heat stroke in children\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H3#H3\">",
"     \"Heat illness (other than heat stroke) in children\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160144498\">",
"    <span class=\"h1\">",
"     EVALUATION OF FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a sign of underlying disease, the cause of which should be evaluated, particularly if the child is ill-appearing or the fever persists. In most cases, the child has additional symptoms and signs of an acute infection, which can be managed as indicated. However, in some children, particularly children with underlying disease, fever may be a sign of a more serious or even life-threatening process. The evaluation of fever in specific populations of children is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=see_link\">",
"       \"Evaluation and management of fever in the neonate and young infant (less than three months of age)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=see_link\">",
"       \"Fever without a source in children 3 to 36 months of age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=see_link\">",
"       \"Etiologies of fever of unknown origin in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=see_link\">",
"       \"Approach to the child with fever of unknown origin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=see_link\">",
"       \"Management of fever in sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link\">",
"       \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Initial evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"       \"Fever in children with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19255?source=see_link&amp;anchor=H6#H6\">",
"       \"Fever in human immunodeficiency virus-infected infants and children\", section on 'Diagnostic evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is an important clinical sign. The first step in the management of fever is to determine its cause. (See",
"    <a class=\"local\" href=\"#H160144498\">",
"     'Evaluation of fever'",
"    </a>",
"    above.) Once the cause is known, the main reason to treat fever is to improve the child&rsquo;s comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160143751\">",
"    <span class=\"h2\">",
"     Anticipatory guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients, parents, and other caregivers frequently make the decision to treat fever without consulting a healthcare provider. Many patients and caregivers believe that fever is harmful and that temperature elevation requires treatment regardless of its cause or effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ]. Education of patients, parents, and caregivers is required to counter these beliefs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/5,35,38\">",
"     5,35,38",
"    </a>",
"    ]. Such education should be provided at health supervision visits and reinforced during acute visits for acute febrile illnesses.",
"   </p>",
"   <p>",
"    Important components of the anticipatory guidance for fever include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,3,5,35,38\">",
"     1,3,5,35,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever is not an illness, but a physiologic response.",
"     </li>",
"     <li>",
"      In otherwise healthy children, most fevers are self-limited and benign, provided that the cause is known and fluid loss is replaced; fever does not cause brain damage. If there are signs of serious illness a healthcare provider should be consulted.",
"     </li>",
"     <li>",
"      There is no evidence that fever makes the illness worse.",
"     </li>",
"     <li>",
"      Initial measures to reduce the child&rsquo;s temperature include provision of extra fluids and reduced activity.",
"     </li>",
"     <li>",
"      Fever may merit treatment with an antipyretic agent if the child is uncomfortable (as indicated by decreased activity level, decreased fluid intake, etc).",
"     </li>",
"     <li>",
"      Children who are receiving treatment for fever do not need to be awakened to receive the antipyretic agent.",
"     </li>",
"     <li>",
"      Children who are receiving antipyretic medications should not be given combination cough and cold preparations, which often contain antipyretic medications; giving both medications may lead to inadvertent overdose.",
"     </li>",
"     <li>",
"      Antipyretic medications should be dosed according to weight, rather than age. When suggesting the use of antipyretic medications, the risk of under- or overdosing antipyretics can be minimized if the clinician provides written dosing instructions and a measuring device, such as a properly marked syringe (for liquid formulations); the dosing directions and measuring devices that are included with over-the-counter medications are variable and inconsistent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/54\">",
"       54",
"      </a>",
"      ]. The instructions should include which formulation (or which concentration of a liquid formulation); how to measure the appropriate volume (for liquid formulation); how often to administer; how to monitor the response; when to discontinue; and when to contact the healthcare provider.",
"     </li>",
"     <li>",
"      Instructions for safe storage of antipyretic medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antipyretic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipyretic agents treat fever by restoring the thermoregulatory set-point to normal. The most commonly used antipyretic agents in children and adolescents are",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    .",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     Aspirin",
"    </a>",
"    should not be used because of its association with Reye syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine treatment of fever in otherwise normal children is not warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1\">",
"     1",
"    </a>",
"    ]. Decisions regarding the treatment of fever in children should be made on a case-by-case basis depending upon the clinical circumstances (eg, underlying disease, level of discomfort, desire to monitor fever curve, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that reducing fever reduces the morbidity or mortality from a febrile illness (with the possible exception of children with underlying conditions that limit the ability to tolerate increased metabolic demands) or that antipyretic therapy decreases the recurrence of febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=see_link&amp;anchor=H22#H22\">",
"     \"Febrile seizures\", section on 'Antipyresis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential benefits of treating fever with antipyretics include improvement of discomfort and decrease in insensible water loss, which may decrease the risk of dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Antipyretic agents also have analgesic effects, which may enhance their overall effect. Potential downsides of treating fever include delayed identification of an underlying illness and drug toxicity; it is uncertain whether treating fever increases the risk or complications of certain types of infections. (See",
"    <a class=\"local\" href=\"#H48346430\">",
"     'Benefits and harms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Indications for the short-term treatment of fever may include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shock",
"     </li>",
"     <li>",
"      Underlying neurologic or cardiopulmonary disease, or other condition with increased metabolic rate (eg, burn, postoperative state)",
"     </li>",
"     <li>",
"      Alteration in fluid and electrolyte balance",
"     </li>",
"     <li>",
"      High fever (ie, &ge;40&ordm;C [104&ordm;F])",
"     </li>",
"     <li>",
"      Discomfort",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with temperature elevation and the possibility of hyperthermia also require treatment, but the treatment of hyperthermia differs from that of fever. Antipyretic medications are ineffective in children with heat stroke and may exacerbate concomitant liver injury or coagulopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H16#H16\">",
"     \"Heat stroke in children\", section on 'Hospital management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H3#H3\">",
"     \"Heat illness (other than heat stroke) in children\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of antipyretic agent for children with underlying medical conditions may be influenced by the underlying medical conditions (eg, avoidance of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in children with liver failure) or desire to avoid drug interactions with chronic medications (eg, selective serotonin reuptake inhibitors may enhance the antiplatelet effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For children without underlying medical conditions, or with underlying medical conditions that do not influence the choice of antipyretic, we suggest beginning treatment with oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    because of its long track record of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is an alternative to acetaminophen, particularly if antiinflammatory effect is desired in addition to antipyresis.",
"    <span class=\"nowrap\">",
"     Patient/parent",
"    </span>",
"    preference is a major factor in the choice of antipyretic because",
"    <span class=\"nowrap\">",
"     patients/parents",
"    </span>",
"    frequently make the decision to treat fever without consulting a healthcare provider. (See",
"    <a class=\"local\" href=\"#H70204935\">",
"     'Acetaminophen'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H70205006\">",
"     'Ibuprofen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the temperature remains elevated and the child&rsquo;s discomfort is not improved three to four hours after administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , it is reasonable to",
"    <strong>",
"     switch",
"    </strong>",
"    from acetaminophen to ibuprofen or ibuprofen to acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H673057897\">",
"     'Treatment response'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We do not suggest combining or alternating",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    because of the potential for dosing confusion, increased toxicity, and contribution to fever phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/3,38,55\">",
"     3,38,55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H70205060\">",
"     'Combining or alternating therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In randomized trials,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    are more effective in reducing temperature than placebo; ibuprofen is slightly more effective and longer-lasting than acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/56-61\">",
"     56-61",
"    </a>",
"    ]. Randomized trials comparing combining or alternating acetaminophen and ibuprofen with single-agent therapy have inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/55,62-67\">",
"     55,62-67",
"    </a>",
"    ]. It is not clear that the difference in temperature reduction with the different regimens is clinically important. Few trials have evaluated improvement in the child&rsquo;s comfort, which is a more relevant outcome than magnitude of temperature reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    has generalized antiinflammatory effects, whereas",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    does not. In an individual case, antiinflammatory effects may be an advantage or a disadvantage. On one hand, inflammation is a major cause of tissue injury and patient discomfort. On the other hand, inflammation is part of the immunologic response.",
"   </p>",
"   <p>",
"    Given the relatively small difference in efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , the choice of agent is based upon the potential toxicity with therapeutic dosing. Appropriate therapeutic doses of acetaminophen and ibuprofen are remarkably free of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/3,61,68-70\">",
"     3,61,68-70",
"    </a>",
"    ]. However, acetaminophen has a longer track record of safety than ibuprofen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518585245\">",
"    <span class=\"h3\">",
"     Antipyretic regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70204935\">",
"    <span class=\"h4\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most children with fever who are treated with an antipyretic agent, we suggest oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    because of its long track record of safety at therapeutic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    generally is not recommended for infants younger than three months of age unless they have been examined by a healthcare provider because fever may be the only sign of serious infection in such infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link&amp;anchor=H9#H9\">",
"     \"Definition and etiology of fever in neonates and infants (less than three months of age)\", section on 'Serious bacterial infection'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum dose 800 mg to 1 g) orally every four to six hours (with no more than five doses in a 24-hour period) with a maximum daily dose of 90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. We do not recommend a &ldquo;loading dose&rdquo; (eg, an initial dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    of acetaminophen for routine clinical care because it may increase the risk of dosing confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 80 percent of febrile children who are treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    have a reduction in temperature of 1 to 2&deg;C (1.8 to 3.6&deg;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38,71\">",
"     38,71",
"    </a>",
"    ]. Acetaminophen begins to work in 30 to 60 minutes and has its peak effect in three to four hours. The duration of action is four to six hours.",
"   </p>",
"   <p>",
"    When administered at appropriate doses,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is remarkably free of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/61,68\">",
"     61,68",
"    </a>",
"    ]. An association between acetaminophen and asthma has been described, but causality has not been demonstrated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H24#H24\">",
"     \"Risk factors for asthma\", section on 'Acetaminophen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overdose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be lethal. Overdose may occur if acetaminophen is administered simultaneously with combination cough and cold remedies that contain acetaminophen, with unsupervised ingestion, and with unclear instructions for administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=see_link&amp;anchor=H5084922#H5084922\">",
"     \"Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70205006\">",
"    <span class=\"h4\">",
"     Ibuprofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    as the initial antipyretic agent when antipyretic and antiinflammatory activity are desired (eg, in children with juvenile arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum dose 600 mg) orally every six hours with a maximum daily dose of 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to 2.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Ibuprofen begins to work in &lt;60 minutes and has its peak effect (decline in temperature of 1 to 2&deg;C (1.8 to 3.6&deg;F)) in three to four hours. The duration of action is six to eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38,71\">",
"     38,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    generally is not recommended for infants younger than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Such infants have limited renal function relative to older infants and children and potentially are at increased risk for renal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    may include gastritis and gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/72\">",
"     72",
"    </a>",
"    ]. When administered at appropriate doses and taken with food, ibuprofen usually is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/61,69\">",
"     61,69",
"    </a>",
"    ]. However, acute kidney injury has been reported following appropriate doses of ibuprofen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/73\">",
"     73",
"    </a>",
"    ]. Anecdotal reports have linked nonsteroidal antiinflammatory drugs with the development or more rapid progression of necrotizing fasciitis due to group A streptococci in children with varicella [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. However, a review of the literature, including five prospective studies, did not demonstrate a correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overdose may occur if",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    is administered simultaneously with combination cough and cold remedies that contain ibuprofen, with unsupervised ingestion, and unclear instruction for administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Overdose of ibuprofen appears more easily managed than overdose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43974?source=see_link&amp;anchor=H13384251#H13384251\">",
"     \"Management of ibuprofen poisoning in children and adolescents\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43974?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of ibuprofen poisoning in children and adolescents\", section on 'Clinical features of acute overdose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70205060\">",
"    <span class=\"h4\">",
"     Combining or alternating therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest combining or alternating therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    to treat fever in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/3,38,55,77\">",
"     3,38,55,77",
"    </a>",
"    ]. Although alternating acetaminophen and ibuprofen is a common practice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/35,78-80\">",
"     35,78-80",
"    </a>",
"    ], the evidence is insufficient to support or refute its efficacy and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/77\">",
"     77",
"    </a>",
"    ]. Until additional information is available, the practice of combining or alternating acetaminophen and ibuprofen should be undertaken with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics clinical report on fever and antipyretic use in children suggests that combined treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    may increase the possibility of inaccurate dosing and may contribute to &ldquo;fever phobia&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. The National Institute for Health and Clinical Excellence advises against the use of combination acetaminophen and ibuprofen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/3\">",
"     3",
"    </a>",
"    ]. If the decision is made to use combined therapy, dosing instructions and intervals must be thoroughly explained. (See",
"    <a class=\"local\" href=\"#H160143751\">",
"     'Anticipatory guidance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Parents report alternating therapy at intervals ranging from two to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Published studies evaluating the efficacy of combined therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    have used different thresholds for fever, sites of temperature measurement (eg, rectal, axillary), dosing regimens, and periods of observation for outcome assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/55,62-67,81\">",
"     55,62-67,81",
"    </a>",
"    ]. Two trials found no difference between combination therapy and single-agent therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/62,65\">",
"     62,65",
"    </a>",
"    ]. Five found combining or alternating antipyretics to be associated with more rapid reduction of fever, lower mean temperature,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    longer duration of antipyresis than single-agent therapy with acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/63,66,67\">",
"     63,66,67",
"    </a>",
"    ] or ibuprofen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/63,64,81\">",
"     63,64,81",
"    </a>",
"    ]. However, the dosing intervals in one of the trials were longer, and the doses lower, than those that are typically used for single-agent therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, the observations may not be clinically significant; in one of the trials that demonstrated a temperature reduction benefit, the parents did not perceive a difference in the effectiveness of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data about the safety of combined therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , but there are several theoretical risks, particularly in children with volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. No major adverse events were reported in any of the randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/55,77\">",
"     55,77",
"    </a>",
"    ]. In one of the trials, mild elevation in liver enzymes occurred in eight children (1.7 percent), and mildly abnormal renal function was observed in 14 children (3 percent); the abnormalities resolved by 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160145086\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of administration of antipyretic therapy depends upon the child&rsquo;s response; the end-point is the child&rsquo;s comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Prolonged use of antipyretic agents generally is not necessary because most febrile illnesses in children are self-limited viral infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H673057897\">",
"    <span class=\"h3\">",
"     Treatment response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with antipyretic agents should make the febrile child more comfortable. It is more important for caregivers to monitor the child&rsquo;s general appearance (for signs of serious illness such as lethargy, stiff neck, altered mental status, petechial or purpuric rash, etc), activity level, and fluid intake than to monitor the temperature curve. With either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , a response should be seen within 60 minutes; the response peaks in three to four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. If the temperature remains elevated and the child&rsquo;s discomfort is not improved three to four hours after administration of acetaminophen or ibuprofen, some experts would suggest switching from acetaminophen to ibuprofen or ibuprofen to acetaminophen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. There are no published studies to evaluate the safety or efficacy of this practice; however, in theory, some fevers may respond better to one antipyretic agent than another.",
"   </p>",
"   <p>",
"    Persistence of a febrile illness beyond four or five days, a marked increase in the height of the maximum fever during the course of the illness, or the development of new localizing symptoms should raise concerns about alternative diagnoses or bacterial superinfection, which should be evaluated by a healthcare provider (or re-evaluated by a healthcare provider if the child was seen at the onset of illness) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518585620\">",
"    <span class=\"h3\">",
"     Use in young infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics clinical report on fever and antipyretic use in children suggests that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    not be administered to infants younger than three months and that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    not be administered to children younger than six months without evaluation by a clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"     38",
"    </a>",
"    ]. Fever may be the only sign of serious infection in a young infant, and such infections should be excluded before symptomatic treatment of fever is initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=see_link&amp;anchor=H9#H9\">",
"     \"Definition and etiology of fever in neonates and infants (less than three months of age)\", section on 'Serious bacterial infection'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Decisions regarding the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in infants younger than three months after serious infection has been excluded should be made on a case-by-case basis. The safety of acetaminophen in young infants can be extrapolated from its use as an analgesic in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35114?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention and treatment of neonatal pain\", section on 'Acetaminophen'",
"    </a>",
"    .) However, there is little information about its efficacy as an antipyretic. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     External cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;External cooling is the treatment of choice for heat stroke and other forms of heat illness in which rapid cooling is necessary to prevent end-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H18#H18\">",
"     \"Heat stroke in children\", section on 'Rapid cooling'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=see_link&amp;anchor=H3#H3\">",
"     \"Heat illness (other than heat stroke) in children\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not routinely suggest external cooling for temperature reduction in previously well infants and children with a febrile illness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/3\">",
"     3",
"    </a>",
"    ]. In randomized trials comparing the combination of tepid sponging and antipyretic therapy to antipyretic therapy alone, the added benefit of tepid sponging in temperature reduction was short-lived, and sponging was associated with increased discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    External cooling may be used as an adjunct to antipyretic therapy for children in whom more rapid and greater reduction of body temperature is necessary than can be achieved with antipyretic agents alone. In such cases, antipyretic agents should be administered at least 30 minutes before external cooling [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/5\">",
"     5",
"    </a>",
"    ]. Antipyretic agents are necessary to reset the thermoregulatory set-point, without which external cooling will result in an increase in heat production [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible indications for concomitant antipyretic administration and mechanical cooling in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncertainty about the cause of elevated temperature (heat illness versus fever) (see",
"      <a class=\"local\" href=\"#H70202193\">",
"       'Hyperthermia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fever combined with a component of heat illness (eg, from over-wrapping, hypovolemia, or drugs such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Underlying neurologic disorder, in which the child may have abnormal temperature control and poor response to antipyretic agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When mechanical cooling is necessary to treat fever, we suggest sponging with comfortably warm or tepid water (generally around 30&ordm;C [85&ordm;F]). Sponging is more effective than immersion because evaporation from the skin augments heat loss. Although temperature reduction may be faster with cold water, sponging with cold water is also more uncomfortable. Alcohol should not be used, because its fumes are absorbed across the alveolar membrane and possibly across the skin, resulting in central nervous system toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/8/18570/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cooling blankets can be useful in hospitalized children who are critically ill or who have problems with temperature control (eg, children with acute head injury).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H657237861\">",
"    <span class=\"h2\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practitioners of complementary and alternative therapy may suggest a number of remedies for fever in infants and children (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12405?source=see_link\">",
"     calcium lactate",
"    </a>",
"    ). These remedies have not been studied in clinical trials, and there is little to no information about their efficacy or safety. We do not recommend their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       \"Patient information: Fever in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever is an abnormal increase in body temperature that results from elevation of the hypothalamic set-point (",
"      <a class=\"graphic graphic_algorithm graphicRef80455 \" href=\"UTD.htm?29/42/30382\">",
"       algorithm 1",
"      </a>",
"      ). The magnitude of temperature increase that prompts evaluation depends upon the age of the child and the clinical circumstances. (See",
"      <a class=\"local\" href=\"#H70202186\">",
"       'Fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of fever should be evaluated, particularly in infants younger than three months of age and infants and children with underlying medical conditions that increase the risk of serious infection (eg, sickle cell disease, neutropenia, human immunodeficiency virus infection). (See",
"      <a class=\"local\" href=\"#H160144498\">",
"       'Evaluation of fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decisions regarding the treatment of fever in children should be made on a case-by-case basis. Indications for the treatment of fever may include shock; underlying medical conditions that would be exacerbated by increased metabolic demand; fluid or electrolyte imbalance; temperature &ge;40&ordm;C (104&ordm;F); and discomfort. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of antipyretic agent for children with underlying medical conditions may be influenced by the underlying medical condition and chronic medications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the decision is made to use an antipyretic agent in a child without an underlying medical condition, or with an underlying medical condition that does not influence the choice of antipyretic, we suggest beginning treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The dose is 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose (maximum dose 800 mg to 1 g) orally every four to six hours (with no more than five doses in a 24-hour period; maximum daily dose: 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day up to 4",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H70204935\">",
"       'Acetaminophen'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      is an alternative to acetaminophen, particularly if antiinflammatory effect is desired. The dose of ibuprofen is 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose (maximum dose 600 mg) orally every six hours (maximum daily dose: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      up to 2.4",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H70205006\">",
"       'Ibuprofen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the temperature remains elevated and the child&rsquo;s discomfort is not improved three to four hours after administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , some experts would suggest switching from acetaminophen to ibuprofen or ibuprofen to acetaminophen. (See",
"      <a class=\"local\" href=\"#H673057897\">",
"       'Treatment response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest combining or alternating",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H70205060\">",
"       'Combining or alternating therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged use of antipyretic agents generally is not necessary. Persistence of fever beyond four or five days, a marked increase in the height of the fever during the course of illness, or the development of new localizing symptoms should raise concerns about alternative diagnoses or bacterial superinfection, which should be evaluated. (See",
"      <a class=\"local\" href=\"#H160145086\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not routinely suggest external cooling for temperature reduction in previously well infants and children with a febrile illness (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'External cooling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ward MA, Parcells CL. Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, et al.  (Eds), Saunders Elsevier, 2009. p.105.",
"    </li>",
"    <li>",
"     Health supervision: First week visit. In: Bright Futures Guidelines for Health Supervision, 3rd ed, Hagan JF, Shaw JS, Duncan PM.  (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2008. p.289.",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Feverish illness in children: Assessment and initial management in children younger than 5 years. May 2007. www.nice.org.uk/nicemedia/live/11010/30523/30523.pdf (Accessed on April 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/4\">",
"      Paes BF, Vermeulen K, Brohet RM, et al. Accuracy of tympanic and infrared skin thermometers in children. Arch Dis Child 2010; 95:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/5\">",
"      Schmitt BD. Fever in childhood. Pediatrics 1984; 74:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/6\">",
"      Anagnostakis D, Matsaniotis N, Grafakos S, Sarafidou E. Rectal-axillary temperature difference in febrile and afebrile infants and children. Clin Pediatr (Phila) 1993; 32:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/7\">",
"      Freed GL, Fraley JK. Lack of agreement of tympanic membrane temperature assessments with conventional methods in a private practice setting. Pediatrics 1992; 89:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/8\">",
"      Webb GE. Comparison of esophageal and tympanic temperature monitoring during cardiopulmonary bypass. Anesth Analg 1973; 52:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/9\">",
"      Moran JL, Peter JV, Solomon PJ, et al. Tympanic temperature measurements: are they reliable in the critically ill? A clinical study of measures of agreement. Crit Care Med 2007; 35:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/10\">",
"      Devrim I, Kara A, Ceyhan M, et al. Measurement accuracy of fever by tympanic and axillary thermometry. Pediatr Emerg Care 2007; 23:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/11\">",
"      Nimah MM, Bshesh K, Callahan JD, Jacobs BR. Infrared tympanic thermometry in comparison with other temperature measurement techniques in febrile children. Pediatr Crit Care Med 2006; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/12\">",
"      El-Radhi AS, Patel S. An evaluation of tympanic thermometry in a paediatric emergency department. Emerg Med J 2006; 23:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/13\">",
"      Sehgal A, Dubey NK, Jyothi MC, Jain S. Comparison of tympanic and rectal temperature in febrile patients. Indian J Pediatr 2002; 69:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/14\">",
"      Brennan DF, Falk JL, Rothrock SG, Kerr RB. Reliability of infrared tympanic thermometry in the detection of rectal fever in children. Ann Emerg Med 1995; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/15\">",
"      Hay AD, Peters TJ, Wilson A, Fahey T. The use of infrared thermometry for the detection of fever. Br J Gen Pract 2004; 54:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/16\">",
"      Dodd SR, Lancaster GA, Craig JV, et al. In a systematic review, infrared ear thermometry for fever diagnosis in children finds poor sensitivity. J Clin Epidemiol 2006; 59:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/17\">",
"      Titus MO, Hulsey T, Heckman J, Losek JD. Temporal artery thermometry utilization in pediatric emergency care. Clin Pediatr (Phila) 2009; 48:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/18\">",
"      Hebbar K, Fortenberry JD, Rogers K, et al. Comparison of temporal artery thermometer to standard temperature measurements in pediatric intensive care unit patients. Pediatr Crit Care Med 2005; 6:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/19\">",
"      Schuh S, Komar L, Stephens D, et al. Comparison of the temporal artery and rectal thermometry in children in the emergency department. Pediatr Emerg Care 2004; 20:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/20\">",
"      Al-Mukhaizeem F, Allen U, Komar L, et al. Comparison of temporal artery, rectal and esophageal core temperatures in children: Results of a pilot study. Paediatr Child Health 2004; 9:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/21\">",
"      Callanan D. Detecting fever in young infants: reliability of perceived, pacifier, and temporal artery temperatures in infants younger than 3 months of age. Pediatr Emerg Care 2003; 19:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/22\">",
"      De Curtis M, Calzolari F, Marciano A, et al. Comparison between rectal and infrared skin temperature in the newborn. Arch Dis Child Fetal Neonatal Ed 2008; 93:F55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/23\">",
"      Greenes DS, Fleisher GR. Accuracy of a noninvasive temporal artery thermometer for use in infants. Arch Pediatr Adolesc Med 2001; 155:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/24\">",
"      Siberry GK, Diener-West M, Schappell E, Karron RA. Comparison of temple temperatures with rectal temperatures in children under two years of age. Clin Pediatr (Phila) 2002; 41:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/25\">",
"      Hoffman RJ, Etwaru K, Dreisinger N, et al. Comparison of temporal artery thermometry and rectal thermometry in febrile pediatric emergency department patients. Pediatr Emerg Care 2013; 29:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/26\">",
"      Mackowiak PA, Wasserman SS. Physicians' perceptions regarding body temperature in health and disease. South Med J 1995; 88:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/27\">",
"      Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 1992; 268:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/28\">",
"      Herzog LW, Coyne LJ. What is fever? Normal temperature in infants less than 3 months old. Clin Pediatr (Phila) 1993; 32:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/29\">",
"      Baraff LJ. Management of the febrile child: a survey of pediatric and emergency medicine residency directors. Pediatr Infect Dis J 1991; 10:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/30\">",
"      Dagan R, Sofer S, Phillip M, Shachak E. Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections. J Pediatr 1988; 112:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/31\">",
"      Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med 1993; 22:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/32\">",
"      Herzog L, Phillips SG. Addressing concerns about fever. Clin Pediatr (Phila) 2011; 50:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/33\">",
"      Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis 1999; 179 Suppl 2:S294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/34\">",
"      Trautner BW, Caviness AC, Gerlacher GR, et al. Prospective evaluation of the risk of serious bacterial infection in children who present to the emergency department with hyperpyrexia (temperature of 106 degrees F or higher). Pediatrics 2006; 118:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/35\">",
"      El-Radhi AS. Why is the evidence not affecting the practice of fever management? Arch Dis Child 2008; 93:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/36\">",
"      Klastersky J, Kass EH. Is suppression of fever or hypothermia useful in experimental and clinical infectious diseases? J Infect Dis 1970; 121:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/37\">",
"      Mackowiak PA. Fever: blessing or curse? A unifying hypothesis. Ann Intern Med 1994; 120:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/38\">",
"      Section on Clinical Pharmacology and Therapeutics, Committee on Drugs, Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics 2011; 127:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/39\">",
"      Greisman LA, Mackowiak PA. Fever: beneficial and detrimental effects of antipyretics. Curr Opin Infect Dis 2002; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/40\">",
"      Dixon G, Booth C, Price E, et al. Fever as nature's engine. Part of beneficial host response? BMJ 2010; 340:c450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/41\">",
"      Fowler AW. A/H1N1 flu pandemic. Fever as nature's engine? BMJ 2009; 339:b3874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/42\">",
"      Kluger MJ, Kozak W, Conn CA, et al. The adaptive value of fever. Infect Dis Clin North Am 1996; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/43\">",
"      Small PM, T&auml;uber MG, Hackbarth CJ, Sande MA. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun 1986; 52:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/44\">",
"      Bernheim HA, Kluger MJ. Fever: effect of drug-induced antipyresis on survival. Science 1976; 193:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/45\">",
"      Kluger MJ, Vaughn LK. Fever and survival in rabbits infected with Pasteurella multocida. J Physiol 1978; 282:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/46\">",
"      Banet M. Fever and survival in the rat. The effect of enhancing fever. Pflugers Arch 1979; 381:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/47\">",
"      Clasen RA, Pandolfi S, Laing I, Casey D Jr. Experimental study of relation of fever to cerebral edema. J Neurosurg 1974; 41:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/48\">",
"      Austin TW, Truant G. Hyperthermia, antipyretics and function of polymorphonuclear leukocytes. Can Med Assoc J 1978; 118:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/49\">",
"      Roberts NJ Jr, Steigbigel RT. Hyperthermia and human leukocyte functions: effects on response of lymphocytes to mitogen and antigen and bactericidal capacity of monocytes and neutrophils. Infect Immun 1977; 18:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/50\">",
"      May A, Bauchner H. Fever phobia: the pediatrician's contribution. Pediatrics 1992; 90:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/51\">",
"      Poirier MP, Davis PH, Gonzalez-del Rey JA, Monroe KW. Pediatric emergency department nurses' perspectives on fever in children. Pediatr Emerg Care 2000; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/52\">",
"      Crocetti M, Moghbeli N, Serwint J. Fever phobia revisited: have parental misconceptions about fever changed in 20 years? Pediatrics 2001; 107:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/53\">",
"      Enarson MC, Ali S, Vandermeer B, et al. Beliefs and expectations of Canadian parents who bring febrile children for medical care. Pediatrics 2012; 130:e905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/54\">",
"      Yin HS, Wolf MS, Dreyer BP, et al. Evaluation of consistency in dosing directions and measuring devices for pediatric nonprescription liquid medications. JAMA 2010; 304:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/55\">",
"      Nabulsi M. Is combining or alternating antipyretic therapy more beneficial than monotherapy for febrile children? BMJ 2009; 339:b3540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/56\">",
"      Wilson JT, Brown RD, Kearns GL, et al. Single-dose, placebo-controlled comparative study of ibuprofen and acetaminophen antipyresis in children. J Pediatr 1991; 119:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/57\">",
"      Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med 2004; 158:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/58\">",
"      Walson PD, Galletta G, Braden NJ, Alexander L. Ibuprofen, acetaminophen, and placebo treatment of febrile children. Clin Pharmacol Ther 1989; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/59\">",
"      Sidler J, Frey B, Baerlocher K. A double-blind comparison of ibuprofen and paracetamol in juvenile pyrexia. Br J Clin Pract Suppl 1990; 70:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/60\">",
"      Kauffman RE, Sawyer LA, Scheinbaum ML. Antipyretic efficacy of ibuprofen vs acetaminophen. Am J Dis Child 1992; 146:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/61\">",
"      Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/62\">",
"      Erlewyn-Lajeunesse MD, Coppens K, Hunt LP, et al. Randomised controlled trial of combined paracetamol and ibuprofen for fever. Arch Dis Child 2006; 91:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/63\">",
"      Sarrell EM, Wielunsky E, Cohen HA. Antipyretic treatment in young children with fever: acetaminophen, ibuprofen, or both alternating in a randomized, double-blind study. Arch Pediatr Adolesc Med 2006; 160:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/64\">",
"      Nabulsi MM, Tamim H, Mahfoud Z, et al. Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061]. BMC Med 2006; 4:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/65\">",
"      Lal A, Gomber S, Talukdar B. Antipyretic effects of nimesulide, paracetamol and ibuprofen-paracetamol. Indian J Pediatr 2000; 67:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/66\">",
"      Kramer LC, Richards PA, Thompson AM, et al. Alternating antipyretics: antipyretic efficacy of acetaminophen versus acetaminophen alternated with ibuprofen in children. Clin Pediatr (Phila) 2008; 47:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/67\">",
"      Hay AD, Costelloe C, Redmond NM, et al. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. BMJ 2008; 337:a1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/68\">",
"      Lavonas EJ, Reynolds KM, Dart RC. Therapeutic acetaminophen is not associated with liver injury in children: a systematic review. Pediatrics 2010; 126:e1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/69\">",
"      Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA 1995; 273:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/70\">",
"      Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. Medicine (Baltimore) 2003; 82:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/71\">",
"      McIntyre J, Hull D. Comparing efficacy and tolerability of ibuprofen and paracetamol in fever. Arch Dis Child 1996; 74:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/72\">",
"      Berezin SH, Bostwick HE, Halata MS, et al. Gastrointestinal bleeding in children following ingestion of low-dose ibuprofen. J Pediatr Gastroenterol Nutr 2007; 44:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/73\">",
"      Misurac JM, Knoderer CA, Leiser JD, et al. Nonsteroidal Anti-Inflammatory Drugs Are an Important Cause of Acute&nbsp;Kidney Injury in Children. J Pediatr 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/74\">",
"      Zerr DM, Alexander ER, Duchin JS, et al. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics 1999; 103:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/75\">",
"      Lesko SM, O'Brien KL, Schwartz B, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics 2001; 107:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/76\">",
"      Hall AH, Smolinske SC, Conrad FL, et al. Ibuprofen overdose: 126 cases. Ann Emerg Med 1986; 15:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/77\">",
"      Purssell E. Systematic review of studies comparing combined treatment with paracetamol and ibuprofen, with either drug alone. Arch Dis Child 2011; 96:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/78\">",
"      Mayoral CE, Marino RV, Rosenfeld W, Greensher J. Alternating antipyretics: is this an alternative? Pediatrics 2000; 105:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/79\">",
"      Wright AD, Liebelt EL. Alternating antipyretics for fever reduction in children: an unfounded practice passed down to parents from pediatricians. Clin Pediatr (Phila) 2007; 46:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/80\">",
"      D&iacute;ez Domingo J, Burgos Ram&iacute;rez A, Garrido Garc&iacute;a J, et al. [Use of alternating antipyretics in the treatment of fever in Spain]. An Esp Pediatr 2001; 55:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/81\">",
"      Paul IM, Sturgis SA, Yang C, et al. Efficacy of standard doses of Ibuprofen alone, alternating, and combined with acetaminophen for the treatment of febrile children. Clin Ther 2010; 32:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/82\">",
"      Zaffanello M, Brugnara M, Angeli S, Cuzzolin L. Acute non-oliguric kidney failure and cholestatic hepatitis induced by ibuprofen and acetaminophen: a case report. Acta Paediatr 2009; 98:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/83\">",
"      Del Vecchio MT, Sundel ER. Alternating antipyretics: is this an alternative? Pediatrics 2001; 108:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/84\">",
"      Thomas S, Vijaykumar C, Naik R, et al. Comparative effectiveness of tepid sponging and antipyretic drug versus only antipyretic drug in the management of fever among children: a randomized controlled trial. Indian Pediatr 2009; 46:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/85\">",
"      Alves JG, Almeida ND, Almeida CD. Tepid sponging plus dipyrone versus dipyrone alone for reducing body temperature in febrile children. Sao Paulo Med J 2008; 126:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/86\">",
"      Purssell E. Physical treatment of fever. Arch Dis Child 2000; 82:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/8/18570/abstract/87\">",
"      Moss MH. Alcohol-induced hypoglycemia and coma caused by alcohol sponging. Pediatrics 1970; 46:445.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5989 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18570=[""].join("\n");
var outline_f18_8_18570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703490142\">",
"      TEMPERATURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H703490149\">",
"      Converting between Fahrenheit and Celsius",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48346114\">",
"      TEMPERATURE HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL BODY TEMPERATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10722181\">",
"      ELEVATED BODY TEMPERATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70202186\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48346159\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48346430\">",
"      - Benefits and harms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70202193\">",
"      Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H160144498\">",
"      EVALUATION OF FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT OF FEVER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160143751\">",
"      Anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antipyretic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H518585245\">",
"      - Antipyretic regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70204935\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70205006\">",
"      Ibuprofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H70205060\">",
"      Combining or alternating therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H160145086\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H673057897\">",
"      - Treatment response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H518585620\">",
"      - Use in young infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      External cooling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H657237861\">",
"      Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5989\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5989|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/42/30382\" title=\"algorithm 1\">",
"      Pathways of fever production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5989|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/23/33149\" title=\"figure 1\">",
"      Hypothalamic set-point vs body temperature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5989|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/36/35405\" title=\"table 1\">",
"      Temperature conversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22186?source=related_link\">",
"      Clinical manifestations and diagnosis of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28951?source=related_link\">",
"      Definition and etiology of fever in neonates and infants (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38905?source=related_link\">",
"      Etiologies of fever of unknown origin in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28074?source=related_link\">",
"      Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3226?source=related_link\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19255?source=related_link\">",
"      Fever in human immunodeficiency virus-infected infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21878?source=related_link\">",
"      Heat illness (other than heat stroke) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/1/39961?source=related_link\">",
"      Management of fever in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43974?source=related_link\">",
"      Management of ibuprofen poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35114?source=related_link\">",
"      Prevention and treatment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_8_18571="Causes of hypopituitarism";
var content_f18_8_18571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of hypopituitarism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pituitary diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mass lesions - pituitary adenomas, other benign tumors, cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pituitary surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pituitary radiation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infiltrative lesions - lymphocytic hypophysitis, hemochromatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infarction - Sheehan syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Apoplexy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genetic diseases - pit-1 mutation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hypothalamic diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mass lesions - benign (craniopharyngiomas) and malignant tumors (metastatic from lung, breast, etc.)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Radiation - for CNS and nasopharyngeal malignancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infiltrative lesions - sarcoidosis, Langerhans cell histiocytosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma - fracture of skull base",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infections - tuberculous meningitis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18571=[""].join("\n");
var outline_f18_8_18571=null;
var title_f18_8_18572="Disease sites in BL";
var content_f18_8_18572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease sites at presentation in endemic and sporadic Burkitt lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Site",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Patients with involvement",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Endemic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdomen",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural effusion",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral nodes",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraspinal",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testis",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharynx",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaw",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orbit",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gascoyne RD, Magrath IT, Sehn L. Burkitt lymphoma. In: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18572=[""].join("\n");
var outline_f18_8_18572=null;
var title_f18_8_18573="EuroSCORE risk index";
var content_f18_8_18573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    EuroSCORE risk prediction algorithm for cardiac surgical mortality",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Predictor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk points*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        Per 5 years or part thereof over 60 years",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic pulmonary disease",
"       </td>",
"       <td>",
"        Long-term use of bronchodilators or steroids for lung",
"disease",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Extracardiac",
"arteriopathy",
"       </td>",
"       <td>",
"        Any one or more of the following:",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        carotid occlusion or",
"&gt;50 percent stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        previous or planned",
"intervention on the abdominal aorta, limb arteries or carotids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurological dysfunction",
"       </td>",
"       <td>",
"        Disease severely affecting ambulation or day-to-day",
"functioning",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous cardiac surgery",
"       </td>",
"       <td>",
"        Requiring opening of the pericardium",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum creatinine",
"       </td>",
"       <td>",
"        &gt;200 micromol/L (2.3 mg/dL) preoperatively",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active endocarditis",
"       </td>",
"       <td>",
"        Patient still under antibiotic treatment for",
"endocarditis at the time of surgery",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Critical",
"preoperative state",
"       </td>",
"       <td>",
"        Any one or more of the following:",
"       </td>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ventricular tachycardia or fibrillation or aborted",
"sudden death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        preoperative cardiac massage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        preoperative ventilation before arrival in the",
"anesthetic room",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        preoperative inotropic support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        intraaortic balloon counterpulsation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        preoperative acute renal failure (anuria or oliguria",
"&lt;10 mL/hour)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"       <td>",
"        Rest angina requiring IV nitrates until arrival in the",
"anesthetic room",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        LV dysfunction",
"       </td>",
"       <td>",
"        Moderate or LV ejection fraction 30 to 50 percent",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor or LV ejection fraction &lt;30 percent",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent myocardial infarct",
"       </td>",
"       <td>",
"        &lt;90 days",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary hypertension",
"       </td>",
"       <td>",
"        Systolic pulmonary artery pressure &gt;60 mmHg",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency operation",
"       </td>",
"       <td>",
"        Carried out on referral before the beginning of the",
"next working day",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other than isolated CABG",
"       </td>",
"       <td>",
"        Major cardiac procedure other than or in addition to",
"CABG",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery on thoracic aorta",
"       </td>",
"       <td>",
"        For disorder of ascending, arch or descending aorta",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postinfarct septal rupture",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; LV: left ventricle; CABG: coronary artery bypass grafting.",
"     <br>",
"      * To calculate the estimated perioperative mortality risk, the sum of the risk points is determined. Scores are stratified into low risk (0 to 2 points; estimated mortality 1.3 percent), medium risk (3 to 5 points; estimated mortality 2.9 percent) and high risk (&ge;6 points; estimated mortality 10.9 to 11.5 percent).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nashed SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18573=[""].join("\n");
var outline_f18_8_18573=null;
var title_f18_8_18574="Mean group melatonin";
var content_f18_8_18574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mean group (n = 30) plasma melatonin profiles after melatonin or placebo treatment 30 minutes before bedtime",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86:4727. file://jcem.endojournals.org/. Copyright &copy; 2001 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18574=[""].join("\n");
var outline_f18_8_18574=null;
var title_f18_8_18575="Type III AC joint sprain";
var content_f18_8_18575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Type III acromioclavicular joint sprain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing depicts a type three acromioclavicular (AC) sprain. Both the AC ligament and the coracoclavicular ligament are completely disrupted. The clavicle is displaced superiorly with such injuries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_8_18575=[""].join("\n");
var outline_f18_8_18575=null;
